Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-02-11T11:08:03.713Z Has data issue: false hasContentIssue false

Surface-associated and secreted factors of Streptococcus suis in epidemiology, pathogenesis and vaccine development

Published online by Cambridge University Press:  29 June 2009

Christoph Georg Baums*
Affiliation:
Institut für Mikrobiologie, Zentrum für Infektionsmedizin, Stiftung Tierärztliche Hochschule Hannover, D-30173 Hannover, Germany
Peter Valentin-Weigand
Affiliation:
Institut für Mikrobiologie, Zentrum für Infektionsmedizin, Stiftung Tierärztliche Hochschule Hannover, D-30173 Hannover, Germany
*
*Corresponding author. E-mail: christoph.baums@gmx.de
Rights & Permissions [Opens in a new window]

Abstract

Streptococcus suis is an invasive porcine pathogen associated with meningitis, arthritis, bronchopneumonia and other diseases. The pathogen constitutes a major health problem in the swine industry worldwide. Furthermore, S. suis is an important zoonotic agent causing meningitis and other diseases in humans exposed to pigs or pork. Current knowledge on pathogenesis is limited, despite the enormous amount of data generated by ‘omics’ research. Accordingly, immunprophylaxis (in pigs) is hampered by lack of a cross-protective vaccine against virulent strains of this diverse species. This review focuses on bacterial factors, both surface-associated and secreted ones, which are considered to contribute to S. suis interaction(s) with host factors and cells. Factors are presented with respect to (i) their identification and features, (ii) their distribution among S. suis and (iii) their significance for virulence, immune response and vaccination. This review also shows the enormous progress made in research on S. suis over the last few years, and it emphasizes the numerous challenging questions remaining to be answered in the future.

Type
Review Article
Copyright
Copyright © Cambridge University Press 2009

Introduction

Streptococcus suis is the most important bacterial cause of meningitis in pigs worldwide. Furthermore, various other organs might be infected by this pathogen leading to different pathologies such as arthritis, serositis, endocarditis, otitis media and bronchopneumonia. Typically, these inflammations are acute and fibrinosuppurative (Williams and Blakemore, Reference Williams and Blakemore1990; Madsen et al., Reference Madsen, Svensmark, Elvestad, Aalbaek and Jensen2002; Beineke et al., Reference Beineke, Bennecke, Neis, Schröder, Waldmann, Baumgartner, Valentin-Weigand and Baums2008). S. suis causes diseases in pigs of different ages, including suckling and weaning piglets as well as growers. Importantly, S. suis is not only an invasive pathogen but also a very successful colonizer of mucosal surfaces, in particular the upper respiratory tract. Healthy carrier piglets are the major reservoir of this pathogen and key players in the epidemiology of S. suis diseases (Clifton-Hadley and Alexander, Reference Clifton-Hadley and Alexander1980).

S. suis, in particular serotype 2 strains, might also cause meningitis, septicemia, endocarditis and other diseases in humans. Close contact with pigs, wild boars or pork is considered to be an important risk factor for this zoonosis (Arends and Zanen, Reference Arends and Zanen1988; Baums et al., Reference Baums, Verkühlen, Rehm, Silva, Beyerbach, Pohlmeyer and Valentin-Weigand2007). In Asia, S. suis is classified as an emerging zoonotic pathogen as it was involved in two large outbreaks of severe human infections in 1998 and 2005 in China, and has recently been identified as one of the most important causes of bacterial meningitis in adults (Mai et al., Reference Mai, Hoa, Nga, Linh, Chau, Sinh, Phu, Chuong, Diep, Campbell, Nghia, Minh, Chau, de Jong, Chinh, Hien, Farrar and Schultsz2008; Wertheim et al., Reference Wertheim, Nghia, Taylor and Schultsz2009). Importantly, streptococcal toxic shock-like syndrome (STSS) was observed in numerous cases in the two outbreaks in China (Tang et al., Reference Tang, Wang, Feng, Yang, Song, Chen, Yu, Pan, Zhou, Wang, Wu, Wang, Zhao, Lin, Yue, Wu, He, Gao, Khan, Wang, Zhao, Wang, Wang, Chen and Gao2006). As the outbreaks were associated with a specific sequence type (ST7), it was suggested that ST7 strains carry additional virulence traits responsible for STSS manifestation (Ye et al., Reference Ye, Zhu, Jing, Du, Segura, Zheng, Kan, Wang, Bai, Zhou, Cui, Zhang, Jin, Sun, Luo, Zhang, Gong, Wang, Wang, Sun, Li, Sun, Liu, Dong, Ke, Yuan, Wang, Tian, Wang, Gottschalk and Xu2006; Chen et al., Reference Chen, Tang, Dong, Wang, Feng, Wang, Zheng, Pan, Liu, Li, Song, Zhu, Sun, Feng, Guo, Ju, Ge, Dong, Sun, Jiang, Wang, Yan, Yang, Wang, Gao, Yang, Wang and Yu2007). Genome comparisons revealed a putative pathogenicity island of 89 kb (89K PAI) present in STSS strains 98HAH12 (Chinese outbreak 1998) and O5ZYH33 (Chinese outbreak 2005) but not in the European serotype 2 reference strain P1/7. The 89K PAI carries putative virulence genes, such as those encoding a two-component signal transduction system involved in virulence (Chen et al., Reference Chen, Tang, Dong, Wang, Feng, Wang, Zheng, Pan, Liu, Li, Song, Zhu, Sun, Feng, Guo, Ju, Ge, Dong, Sun, Jiang, Wang, Yan, Yang, Wang, Gao, Yang, Wang and Yu2007; Li et al., Reference Li, Wang, Feng, Pan, Cheng, Wang, Ge, Zheng, Cao, Dong, Liu, Wang, Lin, Du, Gao, Wang, Hu and Tang2008). However, this review does not focus on STSS. For further details on the zoonotic potential of S. suis, the reader is referred to excellent recent reviews (Gottschalk et al., Reference Gottschalk, Segura and Xu2007; Lun et al., Reference Lun, Wang, Chen, Li and Zhu2007).

S. suis is a very heterogeneous species. Thirty-three serotypes have been identified so far. Serotype 2 is worldwide the most important one. In China, serotype 2 accounts for more than 70% of the systemic S. suis diseases in piglets (Wei et al., Reference Wei, Li, Zhang, He, Hua, Xia, Cai, Chen and Jin2009). However, important geographical differences have been documented with regard to prevalences of S. suis serotypes. In some European countries with large pig industries, such as The Netherlands and Germany, serotype 9 has emerged as the most common serotype (Wisselink et al., Reference Wisselink, Smith, Stockhofe-Zurwieden, Peperkamp and Vecht2000). In the United Kingdom, serotypes 1 and 14 were reported to play important roles in invasive S. suis diseases, predominantly in suckling piglets. Serotype 7 strains have been associated frequently with bronchopneumonia in Scandinavia and, to a lesser extent, in Germany (Perch et al., Reference Perch, Pedersen and Henrichsen1983; Aarestrup et al., Reference Aarestrup, Jorsal and Jensen1998; Tian et al., Reference Tian, Aarestrup and Lu2004; Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006). In Canada and the United States, serotypes 2, 1/2 and 3 have been reported to be the most prevalent. Most of the clinical S. suis isolates in Canada were from the lungs of piglets (Galina et al., Reference Galina, Vecht, Wisselink and Pijoan1996; Messier et al., Reference Messier, Lacouture and Gottschalk2008).

This review focuses on surface-associated and secreted factors of S. suis, which have attracted substantial scientific attention during the last few years. Identification (and characterization) of these factors is important for understanding pathogenesis and also for development of a cross-protective vaccine. Therefore, this review describes various S. suis factors, first surface-associated and then secreted factors, with respect to their identification and features, their distribution among S. suis, and their possible significance for pathogenicity, immune response and vaccination. For a more general overview on S. suis, we recommend the review by Higgins and Gottschalk (Reference Higgins, Gottschalk, Straw, Allaire, Mengeling and Taylor2005).

Cell wall and surface-associated factors of S. suis

The capsule

Serotyping of S. suis is based on differences in composition and structure of the polysaccharide capsule. For S. suis serotype 2, it has been demonstrated by two independent laboratories that the capsule is an important virulence factor (Charland et al., Reference Charland, Harel, Kobisch, Lacasse and Gottschalk1998; Smith et al., Reference Smith, Damman, van der Velde, Wagenaar, Wisselink, Stockhofe-Zurwieden and Smits1999). However, unencapsulated S. suis strains might also invade host tissue, though to a lower degree. This was shown by isolation of isogenic unencapsulated mutants from serosa, joints and central nervous system after intranasal application (Smith et al., Reference Smith, Damman, van der Velde, Wagenaar, Wisselink, Stockhofe-Zurwieden and Smits1999). Large differences in virulence have been described for strains belonging to the same serotype (Vecht et al., Reference Vecht, Wisselink, van Dijk and Smith1992), indicating that the capsule of S. suis is not sufficient for full virulence and that other factors have important functions in the pathogenesis of S. suis.

The capsule of serotypes 1 and 2 strains contains N-acetyl neuraminic acid (sialic acid) and four additional sugars, namely glucose, galactose, N-acetyl glucosamine and N-acetyl galactosamine (serotype 1) or rhamnose (serotype 2) (Elliott and Tai, Reference Elliott and Tai1978). Smith et al. (Reference Smith, Damman, van der Velde, Wagenaar, Wisselink, Stockhofe-Zurwieden and Smits1999) sequenced the cps2 locus and identified genes encoding putative glucosyl-, galactosyl-, N-acetylglucosaminyl- and rhamnosyl-transferases (genes cpsE-K). Furthermore, strains of serotypes 1, 2, 14, 27 and 1/2 carry the genes involved in sialic acid synthesis (Smith et al., Reference Smith, de Vries, van't Slot and Smits2000). In many bacteria, surface-associated sialic acid contributes to pathogenesis by interfering with the activation of the alternative complement pathway by increasing the affinity of C3b to factor H (relative to factor B). This prevents formation of the C3 convertase C3bBb thereby limiting C3b deposition on the surface of the pathogen (Marques et al., Reference Marques, Kasper, Pangburn and Wessels1992). In S. suis, sialic acid contributes to the adherence of serotype 2 strains to murine macrophages (Segura and Gottschalk, Reference Segura and Gottschalk2002). However, adherence was not accompanied by phagocytosis. This finding supports the ‘modified Trojan horse theory’, as proposed earlier by Gottschalk and Segura (Reference Gottschalk and Segura2000). The ‘modified Trojan horse theory’ suggests that S. suis strains, at least suilysin negative strains (see below), may cross the blood–brain–barrier (BBB) through adherence to immune cells, in particular monocytes, which may function as vehicles for passage through the BBB. However, there is also evidence for invasion of choroid plexus epithelial cells and directed transport of S. suis through these cells from the basolateral to the apical site, which faces the cerebrospinal fluid compartment (Tenenbaum et al., Reference Tenenbaum, Papandreou, Gellrich, Friedrichs, Seibt, Adam, Wewer, Galla, Schwerk and Schroten2009).

In contrast to the wild-type, isogenic unencapsulated mutants of serotype 2 strains were efficiently eliminated by primary alveolar macrophages (Smith et al., Reference Smith, Damman, van der Velde, Wagenaar, Wisselink, Stockhofe-Zurwieden and Smits1999) as well as by the murine macrophage cell line J774 (Segura et al., Reference Segura, Cleroux and Gottschalk1998). Segura et al. (Reference Segura, Gottschalk and Olivier2004) found that, unlike the encapsulated wild-type strain, the unencapsulated mutant-induced phosphorylation of the phosphatidylinositol-3 kinase downstream kinases Akt and PKCα in J774 macrophages, indicating the importance of these signaling pathways in phagocytosis of unencapsulated S. suis strains. Furthermore, in macrophages deficient in a tyrosine phosphatase (SHP-1), phagocytosis of an encapsulated S. suis wild-type strain was significantly increased. This was associated with Akt phosphorylation, suggesting that capsule-mediated resistance to phagocytosis involves activation of SHP-1 (Segura et al., Reference Segura, Gottschalk and Olivier2004).

The capsule of S. suis might also have other important immunomodulatory functions. As cell wall components of S. suis induce a significant release of proinflammatory cytokines (tumor necrosis factor-α (TNF-α), IL-1β and IL6) and chemokines (IL-8 and monocyte chemoattractant protein 1 (MCP-1)) by host cells, the capsule might reduce the production of such cytokines by blocking the interaction of cell wall components with pattern-recognition receptors, most importantly Toll-like receptor (TLR)2. On the other hand, the capsule of S. suis serotype 2 itself induces macrophage MCP-1 release through a TLR2- and MyD88-independent pathway (Graveline et al., Reference Graveline, Segura, Radzioch and Gottschalk2007). The authors discussed induction of MCP-1 release as part of the mechanism used by S. suis to translocate the BBB, as brain microvascular endothelial cells (BMECs) were shown to alter expression of tight junction-associated proteins in response to MCP-1 in vitro (Song and Pachter, Reference Song and Pachter2004).

Adhesion of encapsulated serotype 2 strains of S. suis to epithelial cells is generally low, with values below 5% (Lalonde et al., Reference Lalonde, Segura, Lacouture and Gottschalk2000) or about 1% (Benga et al., Reference Benga, Goethe, Rohde and Valentin-Weigand2004). In contrast, unencapsulated strains, including isogenic cps2 mutants, show adherence of 15–60% (Benga et al., Reference Benga, Goethe, Rohde and Valentin-Weigand2004). Interestingly, capsule expression was reported to interfere with adhesion to BMECs of porcine (Vanier et al., Reference Vanier, Segura, Friedl, Lacouture and Gottschalk2004) but not of human origin (Charland et al., Reference Charland, Nizet, Rubens, Kim, Lacouture and Gottschalk2000). It was suggested that porcine, but not human BMECs, might express an important receptor molecule that is recognized by unencapsulated but not encapsulated S. suis strains (Vanier et al., Reference Vanier, Segura, Friedl, Lacouture and Gottschalk2004). However, such a receptor has not been identified and, furthermore, in such a case one would expect lower adhesion values of the unencapsulated strains to human than to porcine BMECs.

Norton et al. (1999) described invasion of the epithelial cell line HEp2 by encapsulated S. suis serotype 2 strains, in contrast to observations published for various epithelial cell lines by other laboratories (Lalonde et al., Reference Lalonde, Segura, Lacouture and Gottschalk2000; Benga et al., Reference Benga, Goethe, Rohde and Valentin-Weigand2004). However, unencapsulated S. suis strains, including an isogenic cps2 mutant, have been demonstrated to be invasive, most likely through receptor-mediated endocytosis. A plausible explanation for the different phenotypes of encapsulated and unencapsulated S. suis strains might be that S. suis down-regulates capsule expression for increased adhesion to epithelial cells and upregulates it for protection against phagocytosis as it enters the bloodstream (Gottschalk and Segura, Reference Gottschalk and Segura2000). Accordingly, an increased thickness of the capsule was demonstrated during cultivation of S. suis in liquid media supplemented with serum (Wibawan and Lammler, Reference Wibawan and Lammler1994). Furthermore, increased thickness of the capsule was also noted during growth in the intra-peritoneal cavities in rats and pigs (Quessy et al., Reference Quessy, Dubreuil, Jacques, Malouin and Higgins1994; Charland et al., Reference Charland, Kobisch, Martineau-Doize, Jacques and Gottschalk1996). Interestingly, Smith et al. (Reference Smith, Buijs, de Vries, Wisselink, Stockhofe-Zurwieden and Smits2001) identified an in vivo-induced gene that encodes a protein highly homologous to CpsY, a regulator of capsule expression in Streptococcus agalactiae (73% identity). Further evidence for capsule regulation in S. suis is provided by a recent study on the orphan response regulator CovR (Pan et al., Reference Pan, Ge, Li, Wu, Wang, Wang, Feng, Yin, Zheng, Cheng, Sun, Ji, Hu, Shi, Feng, Hao, Dong, Hu and Tang2009). The ΔcovR mutant showed a thicker capsule and longer chains. This was in agreement with the finding that cps2C and the gene encoding CMP-N-acetylneuraminic acid synthetase were among the upregulated genes in the ΔcovR mutant. The gene cps2C has been proposed to be involved in chain length determination and export of polysaccharides for capsule production (Smith et al., Reference Smith, Damman, van der Velde, Wagenaar, Wisselink, Stockhofe-Zurwieden and Smits1999).

The capsule of S. suis is poorly immunogenic. Sera from convalescent or bacterin immunized piglets generally have very low specific antibody titers directed against the capsular polysaccharides (Campo Sepulveda et al., Reference Campo Sepulveda, Altman, Kobisch, D'Allaire and Gottschalk1996; Wisselink et al., Reference Wisselink, Vecht, Stockhofe-Zurwieden and Smith2001; Baums et al., Reference Baums, Kock, Beineke, Bennecke, Goethe, Schroder, Waldmann and Valentin-Weigand2009). Immunization of piglets with polysaccharides elicited opsonizing antibodies only in the presence of Feunds' incomplete adjuvant (Elliott et al., Reference Elliott, Clifton-Hadley and Tai1980). We induced very high capsule-specific serum IgG titers through immunization with conjugated serotype 2 capsular polysaccharides. The respective sera caused opsonization of the homologous serotype 2, but not the heterologous serotype 9 strain, and subsequent killing by porcine neutrophils (Baums et al., Reference Baums, Kock, Beineke, Bennecke, Goethe, Schroder, Waldmann and Valentin-Weigand2009). Therefore, we think that a combination of conjugated polysaccharides from different serotypes might elicit protection in swine against S. suis, similar to immunoprophylaxis of pneumococcal infections in humans.

Peptidoglycan

In the cell wall of Gram-positive bacteria glycan strands consisting of alternating β-1,4-linked N-acetylglucosamine and N-acetylmuramic acid are cross-linked by short peptide chains (Vollmer et al., Reference Vollmer, Blanot and de Pedro2008). Fittipaldi et al. (Reference Fittipaldi, Sekizaki, Takamatsu, Dominguez-Punaro, Harel, Bui, Vollmer and Gottschalk2008a) sinvestigated muropeptides of S. suis using two different experimental approaches. The muropeptides had mainly D-isoglutamine at position 2 and L-lysine at position 3 of the peptide stem. In contrast to most other Gram-positive bacteria, S. suis peptidoglycan lacks interpeptide bridges but contains direct 3–4 cross-links. By high-sensitive Fourier transform mass spectrometry, the authors were able to detect N-deacetylated muropeptides in very low quantities in S. suis (probably below 1% of the total muropeptides). N-deacetylated peptidoglycan was not detectable in an S. suis ΔpgdA mutant confirming the proposed function of the protein encoded by the pgdA gene, which was originally identified as a gene upregulated upon interaction with porcine BMECs (Fittipaldi et al., Reference Fittipaldi, Gottschalk, Vanier, Daigle and Harel2007). The peptidoglycan polysaccharide deacetylase PgdA from S. suis shares homology to PgdA from Streptococcus pneumoniae, in particular with respect to catalytic residues, and has also a predicted N-terminal membrane anchor. In general, modification of peptidoglycan through deacetylation results in lysozyme resistance (Vollmer, Reference Vollmer2008). S. suis is very sensitive to lysozyme in vitro, most likely related to the low content of N-deacetylated muropeptides. Furthermore, inactivation of the pgdA gene does not result in increased lysozyme susceptibility. However, these phenotypes might be different in vivo, as pgdA is substantially upregulated upon interaction with host cells and within the host (Fittipaldi et al., Reference Fittipaldi, Sekizaki, Takamatsu, Dominguez-Punaro, Harel, Bui, Vollmer and Gottschalk2008a).

The S. suis pgdA mutant was attenuated in virulence in murine and porcine models of infection. The impairment in virulence was associated with an accelerated decrease in numbers of bacteria in the blood. In accordance, the pgdA mutant was killed efficiently by neutrophils in the presence of naïve serum in vitro, in contrast to the wild-type strain. Furthermore, cytokine production, in particular IFN-γ and IL-6, was severely diminished in CD1 mice infected with the pgdA mutant in comparison to wild-type infected animals (Fittipaldi et al., Reference Fittipaldi, Sekizaki, Takamatsu, Dominguez-Punaro, Harel, Bui, Vollmer and Gottschalk2008a).

Li et al. (Reference Li, Liu, Chen and Zhou2009) performed selective capture of transcribed sequences (SCOTS) to identify genes preferentially expressed under iron starvation. At least six of the 63 identified upregulated genes encode proteins homologous to enzymes involved in cell wall biosynthesis. The upstream sequences of the genes murG (SSU05_0477) and murA (SSU05_1170) contain putative Fur boxes, which suggests that these genes are regulated by the iron-dependent transcriptional regulator Fur (Li et al., Reference Li, Liu, Chen and Zhou2009), and, thus, might be regulated during infection.

Cell wall components of S. suis exacerbate the host inflammatory response to infection as they induce a significant release of proinflammatory cytokines (TNF-α, IL-1β and IL6) and chemokines (IL-8 and MCP-1) (Segura et al., Reference Segura, Vanier, Al Numani, Lacouture, Olivier and Gottschalk2006). Production of these molecules, in particular IL-6, IL-8 and MCP-1, is induced not only in inflammatory cells but also in BMEC (Vadeboncoeur et al., Reference Vadeboncoeur, Segura, Al Numani, Vanier and Gottschalk2003). This induction appears to be cell type specific as it does not occur in human umbilical vein endothelial cells. Production of chemokines by BMECs might be crucial for the inflammatory reaction induced by S. suis invasion of brain tissue and an important source of cytokines and chemokines in the cerebrospinal fluid.

Teichoic and lipoteichoic acids

Teichoic acid (TA) is a secondary polymer of α-glycerol phosphate. Lipoteichoic acid (LTA) contains a glycolipid moiety, resulting in an amphiphilic molecule. Elliot et al. (Reference Elliott, McCarty and Lancefield1977) proposed that LTA from S. suis has a backbone structure similar to TA from Streptococcus pyogenes, but with differences in glucosyl substituents. LTA and TA of S. suis were characterized earlier as antigens recognized by group D antiserum (Elliott et al., Reference Elliott, McCarty and Lancefield1977). Equivocal reactions described in Lancefield typing of S. suis, in particular classification as groups R, S and T, were mainly due to extraction of antigens from capsular material rather than from the cell wall as described by Gottschalk et al. (Reference Gottschalk, Segura and Xu2007) in more detail.

TA and LTA might contribute to the adherence of pathogenic streptococci and staphylococci to host cells. In S. suis, the adhesion to porcine BMEC was reduced by pretreatment of the cells with LTA suggesting that LTA is partially involved in the adhesive phenotype of S. suis to these cells, which form part of the BBB (Vanier et al., Reference Vanier, Segura and Gottschalk2007). Upon interaction with porcine BMECs S. suis upregulates expression of DltA, an enzyme that catalyzes the D-alanylation of LTA (Fittipaldi et al., Reference Fittipaldi, Gottschalk, Vanier, Daigle and Harel2007, Reference Fittipaldi, Sekizaki, Takamatsu, Harel, Dominguez-Punaro, Von Aulock, Draing, Marois, Kobisch and Gottschalk2008b). This modification of LTA is crucial for resistance against cationic antimicrobial peptides, most likely through reduction of the global negative charge of the bacterial envelope. Accordingly, a ΔdltA mutant strain, but not the wild-type, was efficiently killed by porcine neutrophils in the presence of naïve serum and was attenuated in virulence in the CD1 mouse model (Fittipaldi et al., Reference Fittipaldi, Sekizaki, Takamatsu, Harel, Dominguez-Punaro, Von Aulock, Draing, Marois, Kobisch and Gottschalk2008b).

Pili

Pilus formation has been detected in a number of Gram-positive bacteria including the streptococcal species S. pyogenes, S. agalactiae and S. pneumoniae (Telford et al., Reference Telford, Barocchi, Margarit, Rappuoli and Grandi2006). In these streptococci, the genes encoding pili are located on pathogenicity islands. In S. pneumoniae, pili have been demonstrated to be important for adhesion to lung epithelial cells and for virulence in an intranasal challenge experiment with mice (Barocchi et al., Reference Barocchi, Ries, Zogaj, Hemsley, Albiger, Kanth, Dahlberg, Fernebro, Moschioni, Masignani, Hultenby, Taddei, Beiter, Wartha, von Euler, Covacci, Holden, Normark, Rappuoli and Henriques-Normark2006). Ultrastructural investigations of S. suis revealed surface appendages with a length of approximately 250 nm and a width of 2 nm resembling pili of other Gram-positive pathogens (Jacques et al., Reference Jacques, Gottschalk, Foiry and Higgins1990). Accordingly, sequence analysis of the two serotype 2 reference strains P1/7 and 89-1591 indicated presence of a truncated homologue of the S. agalactiae pilus island 2b (PI-2b), which included the two genes encoding the ancillary and major pilin subunits (named srtF cluster by Takamatsu et al., Reference Takamatsu, Nishino, Ishiji, Ishii, Osaki, Fittipaldi, Gottschalk, Tharavichitkul, Takai and Sekizaki2009). Importantly, the sequence of the putative major pilin subunit includes an E-box motif, which has been identified to be crucial for pilus assembly in other bacteria (Ton-That et al., Reference Ton-That, Marraffini and Schneewind2004; Telford et al., Reference Telford, Barocchi, Margarit, Rappuoli and Grandi2006). The first gene (ssu0424 or sipF) of the series of genes that encode the truncated version of PI-2b in S. suis encodes a putative signal peptidase that is preferentially expressed by S. suis upon interaction with porcine BMECs (Fittipaldi et al., Reference Fittipaldi, Gottschalk, Vanier, Daigle and Harel2007). Several mutations are present in the pilus gene cluster of S. suis strains P1/7 and NCTC 10237. Therefore, these strains might not express functional pilus structures. In the future, it is important to clarify whether the gene products of the truncated version of PI-2b in S. suis lead to pilus formation and whether this pilus is important for interaction with host cells and pathogenesis of S. suis.

Takamatsu et al. (Reference Takamatsu, Nishino, Ishiji, Ishii, Osaki, Fittipaldi, Gottschalk, Tharavichitkul, Takai and Sekizaki2009) described a putative pilus gene cluster srtBCD with structural homology to the rlrA island of pneumococci. The cluster lacks a gene encoding a protein homologous to RlrA, but includes genes encoding putative pilin subunit proteins with E-box and LPXTG motifs and three class C sortases.

Sortases

Sortases are transpeptidases that anchor secreted proteins covalently to the cell wall with a C-terminal cell wall sorting signal (CWS). The CWS includes an LPXTG- or related motif followed by a hydrophobic domain and a positively charged tail consisting of at least one arginine or lysine residue. For protein A of Staphylococcus aureus, it has been demonstrated that sortase A specifically cleaves the precursor protein between the threonine and the glycine residues and catalyzes the transfer of the processed protein to the free amino group of a pentaglycine cross-bridge of peptidoglycan (Mazmanian et al., Reference Mazmanian, Liu, Ton-That and Schneewind1999; Ton-That et al., Reference Ton-That, Liu, Mazmanian, Faull and Schneewind1999). S. suis serotype 2 carries five to six genes (srtA–F) encoding putative sortases, which is exceptional for streptococci (Osaki et al., Reference Osaki, Takamatsu, Shimoji and Sekizaki2002; Wang et al., Reference Wang, Li, Feng, Zheng, Dong, Pan, Cheng, Dong, Hu, Feng, Ge, Liu, Wang, Cao, Hu and Tang2009). The gene srtA was detected in S. suis strains of 28 different serotypes indicating that the gene is present in most if not all S. suis strains. It shows substantial allelic variation, which has been proposed to be a result of evolutionary divergence rather than recombination (Osaki et al., Reference Osaki, Takamatsu, Shimoji and Sekizaki2003). The S. suis serotype 2 srtA gene displays high homology (65% identity) to the srtA of Streptococcus gordonii. The homology of the other srt genes (srtB–E) to known sortase genes is much lower. Furthermore, the putative S. suis sortases B–E are class C sortases that have a C-terminal hydrophobic domain serving most likely as a membrane anchor (Dramsi et al., Reference Dramsi, Trieu-Cuot and Bierne2005). Osaki et al. (Reference Osaki, Takamatsu, Shimoji and Sekizaki2002) found that more than 15 protein spots in 2D-PAGE of cell wall proteins depended on the presence of the gene encoding sortase A but were independent of other srt genes. Four putative sortase A substrates with a CWS were identified; among these was the muramidase-released protein (MRP, see also Table 1). Furthermore, the CWS-protein surface antigen one (SAO) was also not detectable on the surface of an srtA mutant (Wang et al., Reference Wang, Li, Feng, Zheng, Dong, Pan, Cheng, Dong, Hu, Feng, Ge, Liu, Wang, Cao, Hu and Tang2009).

Table 1. Confirmed (c) and proposed (p) S. suis proteins with a CWS

a The prefixes SSU98 and SSU05 in the ordered locus names have been annotated in the genomes of the two sequenced STSS strains 98HAH12 and O5ZYH33, respectively. Factors are regarded as proposed, if no confirmation of protein expression has been reported.

b The theoretical molecular weight is based on the genome sequence of serotype 2 reference strain P1/7 (www.sanger.ac.uk), if it is not provided by the authors.

c Further genes and pseudogenes encoding putative pilin subunit proteins with CWS have been described (see Table S2 in Takamatsu et al., Reference Takamatsu, Nishino, Ishiji, Ishii, Osaki, Fittipaldi, Gottschalk, Tharavichitkul, Takai and Sekizaki2009, and Table 3 in Wang et al., Reference Wang, Li, Feng, Zheng, Dong, Pan, Cheng, Dong, Hu, Feng, Ge, Liu, Wang, Cao, Hu and Tang2009).

Table 2. Confirmed (c) and proposed (p) surface-associated proteins of S. suis without a CWSFootnote a

a Integral membrane proteins are not included with the exception of a few selected proteins with a C-terminal membrane anchor.

b The prefixes SSU98 and SSU05 in the ordered locus names have been annotated in the genomes of the two sequenced STSS strains 98HAH12 and O5ZYH33, respectively. Factors are regarded as proposed, if no confirmation of protein expression is available.

c These factors were identified as surface-associated factors in S. suis serotype 9 based on an immunoproteomic analysis of cell wall proteins (Wu et al., Reference Wu, Zhang and Lu2008a).

Table 3. Proposed (p) and confirmed (c) secreted factors of S. suis (selection)

a This ORF was annotated as an LPXTG-motif cell wall anchor domain protein in SsuiDRAFT_3692 of strain 89/1591. However, the putative Gram-positive anchor identified by Pfam 5 is localized between amino acids 67 and 106 at the N-terminus.

b Cell-associated activity of DPP IV and Arg-aminopeptidase was also reported in the respective publications.

c An ORF encoding a putative IgG-binding protein is annotated in the genome of S. suis 98015 (accession no. DQ410872), but experimental evidence regarding IgG binding of this factor has not been published.

d Bacteriocin-like inhibitory substances.

Isogenic srtA serotype 2 mutants are attenuated in adherence to and invasion of host cells including porcine BMECs, indicating that CWS proteins are involved in this interaction (Vanier et al., Reference Vanier, Sekizaki, Dominguez-Punaro, Esgleas, Osaki, Takamatsu, Segura and Gottschalk2008; Wang et al., Reference Wang, Li, Feng, Zheng, Dong, Pan, Cheng, Dong, Hu, Feng, Ge, Liu, Wang, Cao, Hu and Tang2009). Accordingly, binding to plasma and cellular fibronectin as well as to collagen type I diminished in the srtA mutant. However, the binding of these host proteins is not completely abrogated in the srtA mutant, suggesting that the other sortases might also be involved in anchoring of adhesins or that non-CWS adhesins are also important for this phenotype (Vanier et al., Reference Vanier, Sekizaki, Dominguez-Punaro, Esgleas, Osaki, Takamatsu, Segura and Gottschalk2008).

Surprisingly, the isogenic srtA serotype 2 mutant was as virulent as the wild-type in the CD1 mice model (Vanier et al., Reference Vanier, Sekizaki, Dominguez-Punaro, Esgleas, Osaki, Takamatsu, Segura and Gottschalk2008). In contrast, intravenous infection of piglets with an srtA mutant of the Chinese STSS reference strain O5ZYH33 suggested attenuation in virulence. Competitive challenge experiments with the wild-type strain suggested that the srtA mutant is primarily attenuated in colonization of the brain and the lung (Wang et al., Reference Wang, Li, Feng, Zheng, Dong, Pan, Cheng, Dong, Hu, Feng, Ge, Liu, Wang, Cao, Hu and Tang2009). Because of the contradictory findings, it is difficult at present to assess the relevance of sortase A function in the pathogenesis of S. suis.

Proteins with a CWS (LPXTG-motif)

In silico analysis of the genome of the Chinese serotype 2 reference strain O5ZYH33 revealed 33 putative cell wall-anchored proteins containing an LPXTG- or related motif (Wang et al., Reference Wang, Li, Feng, Zheng, Dong, Pan, Cheng, Dong, Hu, Feng, Ge, Liu, Wang, Cao, Hu and Tang2009). As described above, LPXTG-motifs, in particular CWS, indicate covalent linkage of these proteins to the cell wall. In other streptococci, numerous LPXTG-proteins have been demonstrated to be involved in binding of extracellular matrix proteins and adhesion to host cells. Though it is accepted that S. suis interacts with extracellular host proteins and cells (Esgleas et al., Reference Esgleas, Lacouture and Gottschalk2005), conclusive evidence for such a function is lacking for any of the putative adhesins described in S. suis. Following, surface-associated factors of S. suis are described that contain a CWS (see also Table 1).

MRP

Differences in virulence between S. suis serotype 2 strains are associated with expression of MRP and extracellular factor (EF). However, MRP is not an essential virulence factor for S. suis serotype 2, as an isogenic mrp mutant was as virulent as the wild-type strain (Smith et al., Reference Smith, Vecht, Wisselink, StockhofeZurwieden, Biermann and Smits1996). The 136 kDa MRP was discovered as a factor released from virulent serotype 2 strains after muramidase treatment. The protein is also detectable in stationary-growth-phase culture supernatants of MRP expressing serotype 2 strains (Vecht et al., Reference Vecht, Wisselink, Jellema and Smith1991). Sequence analysis revealed a signal sequence and a CWS (Smith et al., Reference Smith, Vecht, Gielkens and Smits1992). Accordingly, MRP has been demonstrated to be a substrate of sortase A (Osaki et al., Reference Osaki, Takamatsu, Shimoji and Sekizaki2002). The mature MRP contains at the C-terminus a proline rich region followed by three repeats. The function of MRP is unknown. Fibronectin binding was not detectable (Smith et al., Reference Smith, Vecht, Gielkens and Smits1992).

When compared to the early exponential growth phase in vitro expression of MRP is induced during infection (Tan et al., Reference Tan, Liu, Jin, Liu, Chen, Wu, Fu, Bei and Chen2008b). Accordingly, we demonstrated in situ MRP expression in fibrinosuppurative meningitis and granulomatous encephalitis lesions caused by experimental S. suis infections (Beineke et al., Reference Beineke, Bennecke, Neis, Schröder, Waldmann, Baumgartner, Valentin-Weigand and Baums2008).

Expression of the 136 kDa MRP was found among strains of serotypes 1, 2, 1/2, 14 and 15. Large (MRP*) and small (MRPs) size variants have been described, which were detectable in S. suis strains of nearly all serotypes investigated (Wisselink et al., Reference Wisselink, Smith, Stockhofe-Zurwieden, Peperkamp and Vecht2000). Serotype 1 MRPs EF+ strains caused high mortality in germfree piglets within 48 h after intranasal infection at a dose as low as 104 CFU. Noteworthy, an isogenic mrp s mutant of such a serotype 1 strain was not attenuated in virulence (Smith et al., Reference Smith, Vecht, Wisselink, StockhofeZurwieden, Biermann and Smits1996). In central Europe, approximately 20% of the invasive S. suis diseases are caused by MRP* EF− serotype 9 strains (Wisselink et al., Reference Wisselink, Smith, Stockhofe-Zurwieden, Peperkamp and Vecht2000; Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006). Duplication of intermediate and repetitive sequences present in mrp coding for the 136 kDa protein is responsible for the larger size of MRP* in these serotype 9 strains (Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006). In serotype 7 strains, size variation of mrp is very pronounced. However, Western blot analysis suggested that most of these mrp variant genes in serotype 7 strains are silent (Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006).

Determination of the mrp and epf genotypes (or the respective phenotypes) in addition to serotyping has been performed in numerous epidemiological studies (Gottschalk et al., Reference Gottschalk, Lebrun, Wisselink, Dubreuil, Smith and Vecht1998; Wisselink et al., Reference Wisselink, Smith, Stockhofe-Zurwieden, Peperkamp and Vecht2000; Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006; Wei et al., Reference Wei, Li, Zhang, He, Hua, Xia, Cai, Chen and Jin2009). It is now included in routine diagnosis of S. suis in several laboratories. This differentiation allows identification of the two most important European S. suis pathotypes, mrp+ epf+ cps2 (MRP+ EF+ serotype 2) and mrp* epfcps9 (MRP* EF− serotype 9) strains. However, due to some open questions interpretation of typing results remains difficult. Though mrp (MRP) is a virulence marker in serotype 2 strains, it is not clear whether this is also the case for other serotypes. Furthermore, MRP+ EF− serotype 2 strains have not been compared to other serotype 2 phenotypes (MRP+ EF+, MRP+ EF* and MRP− EF−) in experimental infections with piglets, which makes it difficult to assess the virulence of this particular phenotype. Recent experimental infections of BALB/c mice suggested that mrp+ epfcps2 strains are substantially less virulent than mrp+ epf+ cps2 genotype strains (Wei et al., Reference Wei, Li, Zhang, He, Hua, Xia, Cai, Chen and Jin2009). However, determination of the virulence of an S. suis strain in mice is problematic, since results obtained from BALB/c mice and piglet infections differ from each other (Vecht et al., Reference Vecht, Stockhofe-Zurwieden, Tetenburg, Wisselink and Smith1997). As mrp seems to be a silent gene in some strains (e.g. serotype 7), it might also be discussed that phenotyping rather than genotyping should be performed in diagnostic laboratories. Nevertheless, for the identification of the two most important European S. suis pathotypes, mrp+ epf+ cps2 and mrp* epfcps9, as well as the highly virulent mrp sepf+ cps1 pathotype, both approaches appear equally reliable (Wisselink et al., Reference Wisselink, Joosten and Smith2002; Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006). Importantly, neither genotyping nor phenotyping of these markers alone allows classification of a strain as avirulent, as MRP and EF are not crucial virulence factors (Smith et al., Reference Smith, Vecht, Wisselink, StockhofeZurwieden, Biermann and Smits1996), and MRP− EF− serotype 2 strains from North America induce disease in experimental infections (Gottschalk et al., Reference Gottschalk, Higgins and Quessy1999).

MRP is a highly immunogenic protein. Convalescent sera from piglets infected with either MRP+ serotype 2 or MRP* serotype 9 strains generally contain high specific antibody titers (Zhang and Lu, Reference Zhang and Lu2007). Furthermore, immunizations with bacterins based on such strains elicited seroconversion against MRP (Wisselink et al., Reference Wisselink, Vecht, Stockhofe-Zurwieden and Smith2001; Baums et al., Reference Baums, Kock, Beineke, Bennecke, Goethe, Schroder, Waldmann and Valentin-Weigand2009).

Geng et al. (Reference Geng, Zhu, Yuan, Zhang, Li, Wang, Zheng, Wei, Cao, Wang and Jiang2008) observed 90% bactericidal activity against S. suis serotype 2 in a whole human blood killing assay with anti-rMRP antisera. The bactericidal activity of sera against 10 other S. suis cell wall-associated proteins was much lower. In contrast, we did not observe elicitation of opsonizing antibodies in piglets by immunization with a subunit vaccine including MRP, though these animals developed high antibody titers against MRP (Baums et al., Reference Baums, Kock, Beineke, Bennecke, Goethe, Schroder, Waldmann and Valentin-Weigand2009). The lack of opsonizing activity in post immune sera of this group correlated with the lack of protection in serotype 2 and 9 challenges. Accordingly, Wisselink et al. (Reference Wisselink, Vecht, Stockhofe-Zurwieden and Smith2001) also found no protection in MRP+ EF+ serotype 2 challenge experiments of piglets after application of a vaccine based on purified MRP, in contrast to immunization with a bacterin and a vaccine containing MRP and EF (Table 4). In conclusion, at present it seems more likely that MRP specific antibodies in swine are not protective, though they are good markers of infection.

Hyaluronidase (HylA)

Hyaluronic acid (HA) is a glycosaminoglycan that constitutes a major part of the extracellular matrix and the capsule of certain bacteria. The majority of S. suis strains of serotypes 3 and 7 degrade HA by secreting a 130 kDa hyaluronidase (also referred to as hyaluronate lyase) (Allen et al., Reference Allen, Lindsay, Seilly, Bolitho, Peters and Maskell2004; King et al., Reference King, Allen, Maskell, Dowson and Whatmore2004). Furthermore, cultivation experiments indicated that these strains ferment the degradation product of HA. In contrast hyaluronidase activity is not detectable in most strains of other serotypes including 1, 1/2, 5, 6, 9, 10, 14 and 22. Some virulent serotype 2 reference strains such as P1/7, and strains of serotypes 1, 1/2, 5 and 14, express truncated versions of the protein, which is not associated with hyaluronidase activity. Sequence analysis of the full length 130 kDa hyaluronidase predicts a CWS (in contrast to the C-terminal truncated versions) (King et al., Reference King, Allen, Maskell, Dowson and Whatmore2004). However, enzyme activity is detectable in the culture supernatant (Allen et al., Reference Allen, Lindsay, Seilly, Bolitho, Peters and Maskell2004). This is in agreement with the presence of MRP and CWS proteins from other bacteria in culture supernatants (Vecht et al., Reference Vecht, Wisselink, Jellema and Smith1991; Courtney et al., Reference Courtney, Hasty, Li, Chiang, Thacker and Dale1999).

The expression pattern of hyaluronidase among different S. suis strains indicates that hyaluronidase activity is not crucial for the pathogenesis of S. suis meningitis and other invasive diseases, as highly virulent S. suis strains lack this activity. On the other hand, it cannot be excluded that expression of hyaluronidase is important for the pathogenesis of diseases (e.g. pneumonia) associated with different pathotypes, in particular serotype 7 (King et al., Reference King, Allen, Maskell, Dowson and Whatmore2004). Noteworthy, high hyaluronidase activity was observed in strains of serotype 7. Interestingly, Allen et al. (Reference Allen, Lindsay, Seilly, Bolitho, Peters and Maskell2004) observed an inverse correlation between the presence of suilysin and hyaluronidase activity. Furthermore, genetic analysis of hylA revealed high diversity in the 5′-end and evidence that recombination has contributed to molecular variation. Some hyl alleles possess direct sequence duplications of 2 or 4 bp, which are known to be intrinsically unstable. It is plausible to speculate that expression of hyaluronidase is regulated by the generation and excision of these repeats during infection (King et al., Reference King, Allen, Maskell, Dowson and Whatmore2004).

SAO

Li et al. (Reference Li, Martinez, Gottschalk, Lacouture, Willson, Dubreuil, Jacques and Harel2006) discovered SAO as an immunogenic protein of S. suis which is recognized by porcine convalescent sera (Table 1). The authors proved surface localization by immuno gold-labeling electron microscopy. The protein contains a CWS and numerous repeats in its C-terminal half. Variations in the number of repeats account for differences in molecular weight observed between SAO variants of different serotypes and within serotype 2 strains (Li et al., Reference Li, Martinez, Gottschalk, Lacouture, Willson, Dubreuil, Jacques and Harel2006; Feng et al., Reference Feng, Zheng, Pan, Sun, Wang, Dong, Ju, Ge, Liu, Liu, Yan, Tang and Gao2007). The function of SAO is still unknown.

Immunization of mice and piglets with rSAO elicited protective immune response against serotype 2 strains expressing different variants of SAO (Li et al., Reference Li, Gottschalk, Esgleas, Lacouture, Dubreuil, Willson and Harel2007). Furthermore, Zhang et al. (Reference Zhang, Chen, Mu, Li, Zheng, Zhao, Chen and Jin2009) described protection against challenges with serotypes 2 and 7 strains in mice after immunization with rSAO. Protection in piglets was observed when using the adjuvant Quil A (Brenntag Biosector, Frederikssund, Denmark), but not with Emulsigen-Plus (MVP Laboratories, Ralston, USA) (Li et al., Reference Li, Martinez, Gottschalk, Lacouture, Willson, Dubreuil, Jacques and Harel2006, Reference Li, Gottschalk, Esgleas, Lacouture, Dubreuil, Willson and Harel2007). In contrast to piglets immunized with SAO and Emulsigen-Plus, application of Quil A elicited an IgG2 dominated immune response. The authors discussed correlation of protection with a putative Th-1 response and induction of opsonizing antibodies. However, we demonstrated that, in contrast to a serotype 2 bacterin, a subunit vaccine including SAO did not elicit opsonizing antibodies or protection against serotype 2 or 9 challenges, despite high SAO specific IgG2 titers (Baums et al., Reference Baums, Kock, Beineke, Bennecke, Goethe, Schroder, Waldmann and Valentin-Weigand2009). The different results on protective properties of SAO might be explained by different experimental conditions used to test vaccine efficacy (Table 4).

Opacity-factor of Streptococcus suis (OFS)

S. suis serotype 2 (multilocus sequence type 1) expresses a surface-associated protein called OFS, which opacifies serum of various species (Baums et al., Reference Baums, Kaim, Fulde, Ramachandran, Goethe and Valentin-Weigand2006, see also Table 1). The protein has structural features of an MSCRAMM, namely a signal sequence, a large N-terminal domain, C-terminal repeats and a CWS. The N-terminal domain is responsible for serum opacification and is homologous to FnBA of Streptococcus dysgalactiae and serum opacity factor (SOF) of S. pyogenes. In contrast to these MSCRAMMs, OFS does not confer binding to fibronectin. This might be explained by substantial sequence deviation found in the repeats of OFS in comparison to the repeats of other MSCRAMMs. Takamatsu et al. (Reference Takamatsu, Osaki, Tharavichitkul, Takai and Sekizaki2008) identified three additional genotypes of ofs. In contrast to the originally described OFS (designated type-1 OFS by Takamatsu et al., Reference Takamatsu, Osaki, Tharavichitkul, Takai and Sekizaki2008), which possesses three C-terminal repetitive sequences, the type-2 OFS is characterized by four repetitive sequences. In strains expressing type-2 OFS, serum opacification activity was detectable in culture supernatants. In contrast, type-1 OFS activity was only detected in SDS-extracts of bacteria. In addition to type-1 and type-2 ofs, other variants of ofs were identified which contain either point mutations or genetic disruptions by insertion elements or rearrangements. Accordingly, these did not express detectable serum opacification activity (Takamatsu et al., Reference Takamatsu, Osaki, Tharavichitkul, Takai and Sekizaki2008).

Using an isogenic ofs in-frame deletion mutant, we demonstrated that OFS is an important virulence factor in S. suis serotype 2 (multilocus sequence type 1). Though few animals developed disease after intranasal infection with the ofs mutant, the majority of piglets did not show any sign of disease, in contrast to the wild-type strain that caused mortalities of 70–90% (Baums et al., Reference Baums, Kaim, Fulde, Ramachandran, Goethe and Valentin-Weigand2006; Kock et al., Reference Kock, Beineke, Seitz, Ganter, Waldmann, Valentin-Weigand and Baums2009). However, the function of OFS in pathogenesis might be restricted to the highly virulent multilocus sequence type (ST) complex 1 as serum opacification activity is not detectable in virulent strains of ST complex 27 (Takamatsu et al., Reference Takamatsu, Osaki, Tharavichitkul, Takai and Sekizaki2008).

Interestingly, the ofs mutant was not attenuated in colonizing the upper respiratory tract and the tonsils. Therefore, we tested the ofs mutant as a live vaccine candidate for intranasal application. The mortality after homologous challenge was lower in the vaccinated piglets than in the control animals; however, this difference was not significant. Furthermore, the serotype 2 ofs mutant vaccine did not elicit protection against the heterologous serotype 9 challenge (Kock et al., Reference Kock, Beineke, Seitz, Ganter, Waldmann, Valentin-Weigand and Baums2009).

Immunization experiments with rOFS demonstrated that the protein is immunogenic (our unpublished results). On the other hand, we could not detect antibody titers against OFS in convalescent sera, suggesting that this protein is expressed only in limited amounts and only during a short period of infection. The possible role of OFS in S. suis–host interactions remains to be elucidated.

Putative cyclic nucleotide phosphodiesterase (SntA)

S. suis sortase A anchors SntA, a putative 2′,3′-cyclic nucleotide 2′-phosphodiesterase, to the cell wall (Osaki et al., Reference Osaki, Takamatsu, Shimoji and Sekizaki2002). The expression of sntA (also called cpdB) is upregulated under iron starvation (Li et al., Reference Li, Liu, Chen and Zhou2009). To the best of our knowledge the function of SntA in S. suis has yet not been identified. As SntA possesses an RGD motif, it is plausible to speculate that SntA might be involved in interaction with host cells by binding to integrin(s) on their surface (Osaki et al., Reference Osaki, Takamatsu, Shimoji and Sekizaki2002).

Proposed and confirmed surface-associated proteins lacking a known CWS

Fibronectin- and fibrinogen-binding protein of S. suis (FBPS)

The gene encoding FBPS was identified by in vivo promoter selection (Smith et al., Reference Smith, Buijs, de Vries, Wisselink, Stockhofe-Zurwieden and Smits2001). Accordingly, Tan et al. (2008b) observed higher expression of fbps in vivo than in early exponential growth phase cultures. Sequence comparisons revealed homology of FBPS with the fibronectin binding proteins FlpA and FBP54 of S. gordonii and S. pyogenes, respectively. This homology is very prominent (80%) in the fibrionogen/fibronectin binding region of FBP54. Accordingly, rFBPS binds to human fibronectin and fibrinogen (de Greeff et al., Reference de Greeff, Buys, Verhaar, Dijkstra, van Alphen and Smith2002, see also Table 2). S. suis serotype 2 binds to both plasma and cellular fibronectin (Esgleas et al., Reference Esgleas, Lacouture and Gottschalk2005). However, so far it has not been demonstrated that FBPS confers binding of S. suis to fibronectin (or fibrinogen).

The fbps serotype 2 knock-out mutant was tested in a competition challenge experiment with the wild-type strain in four piglets (de Greeff et al., Reference de Greeff, Buys, Verhaar, Dijkstra, van Alphen and Smith2002). The results suggested that the fbps mutant is attenuated in virulence but not in colonization of the tonsils.

The fbps gene is widely distributed among different serotypes of S. suis. It is detectable in virulent, weakly virulent and avirulent serotype 2 strains (de Greeff et al., Reference de Greeff, Buys, Verhaar, Dijkstra, van Alphen and Smith2002). Allelic variation of fbps has not been described. Whether FBPS is expressed in all fbps-positive strains is also unknown.

Convalescent-phase sera recognize FBPS. The protective efficacy of a vaccine based on rFBPS or purified FBPS in pigs has not been reported. Immunization of BALB/c mice with rFBPS did not elicit significant protection against intra-peritoneal challenge with the Chinese STSS reference strain O5ZYH33, in contrast to immunization with other S. suis antigens (Liu et al., Reference Liu, Cheng, Wang, Pan, Cong, Pan, Wang, Zheng, Hu and Tang2009). A subunit vaccine including FBPS and other surface-associated proteins was also not protective in serotypes 2 and 9 challenge experiments of piglets (Baums et al., Reference Baums, Kock, Beineke, Bennecke, Goethe, Schroder, Waldmann and Valentin-Weigand2009, see also Table 4).

Arginine deiminase (ArcA)

Arginine deiminase (ArcA) belongs to the Arginine–Deiminase system (ADS), a catabolic enzymatic pathway known in many bacteria, including streptococci. ADS catalyzes the conversion of arginine to ornithine, carbon dioxide and ammonia, thereby generating ATP (Cunin et al., Reference Cunin, Glansdorff, Pierard and Stalon1986; Zuniga et al., Reference Zuniga, Perez and Gonzalez-Candelas2002).

Some years ago we identified an ADS in S. suis as a temperature-induced and partially cell wall associated enzyme system (Winterhoff et al., Reference Winterhoff, Goethe, Gruening, Rohde, Kalisz, Smith and Valentin-Weigand2002, see also Table 2). It is encoded by three major genes, arcA, arcB and arcC, which are transcribed from an operon (AD operon). arcA codes for an arginine deiminase (AD), arcB for an ornithine-carbamoyltransferase (OCT) and arcC for a carbamate kinase (CK) (Gruening et al., Reference Gruening, Fulde, Valentin-Weigand and Goethe2006). The AD operon is clustered together with a putative arginine–ornithine antiporter (arcD), a putative Xaa-His dipeptidase (arcT) and a putative endo-beta-galactosidase (arcH). The operon seems to be controlled by several factors, including carbon catabolite repression by CcpA, metabolic regulation by an fumarate and nitrate reduction regulator (FNR)-like protein (FlpS) and by the ArgR repressor belonging to the ArgR/AhrC family (Gruening et al., Reference Gruening, Fulde, Valentin-Weigand and Goethe2006).

A putative role of the ADS during streptococcal pathogenesis was first reported for S. pyogenes, since it was shown to be involved in epithelial cell adhesion and invasion of this pathogen (Degnan et al., Reference Degnan, Fontaine, Doebereiner, Lee, Mastroeni, Dougan, Goodacre and Kehoe2000). In S. suis, we have recently found that expression of the ADS favors survival of S. suis in acidified epithelial cell compartments. Furthermore, we observed that mutants defective in different structural and regulators genes of the ADS were defective in production of ammonia and neutralization of low pH during in vitro growth, as well as in survival at low pH, low oxygen and inside HEp-2 epithelial cells (Benga et al., Reference Benga, Goethe, Rohde and Valentin-Weigand2004; Gruening et al., Reference Gruening, Fulde, Valentin-Weigand and Goethe2006). The relevance of the ADS for pathogenesis remains to be elucidated. Nevertheless, expression of ArcA on the streptococcal surface, and the phenotype of AD mutants with respect to biological fitness in in vitro culture and host epithelial cells suggest a role of the ADS in S. suis survival during infection.

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

GAPDH is an enzyme of the glycolytic pathway and, in addition, a surface-associated factor in pathogenic streptococci involved in interaction with host proteins and cells (Pancholi and Fischetti, Reference Pancholi and Fischetti1992). Surface-associated GAPDH was discovered in S. suis as an albumin-binding protein (Quessy et al., Reference Quessy, Busque, Higgins, Jacques and Dubreuil1997). Cloning and sequencing of gapdh from S. suis serotype 2 revealed high homology to the homologous genes of other streptococci, including S. pneumoniae and S. pyogenes (Brassard et al., Reference Brassard, Gottschalk and Quessy2004, see also Table 2). Transposon mutants deficient in the expression of GAPDH were attenuated in the adhesion to embryonic bovine tracheal cells and porcine tracheal rings, suggesting that GAPDH is involved in adhesion to host cells (Brassard et al., Reference Brassard, Gottschalk and Quessy2001). Furthermore, plasminogen binding to the surface of S. suis was reduced by approximately 25% in a gapdh transposon mutant, suggesting that gapdh is also involved in plasminogen acquisition (Jobin et al., Reference Jobin, Brassard, Quessy, Gottschalk and Grenier2004). Plasminogen is a central component of the host fibrinolytic system. Host plasmin activators or bacterial proteases, such as streptokinase, may activate plasminogen generating the serine protease plasmin. Different pathogens exploit the fibrinolytic activity of plasmin(ogen) by binding and activating plasminogen on their surface. In S. suis, activation of surface-bound plasminogen does not occur in the presence of serum, but after addition of urokinase, streptokinase or supernatant from S. dysgalactiae subsp. equisimilis (Jobin et al., Reference Jobin, Brassard, Quessy, Gottschalk and Grenier2004). Interestingly, co-incubation experiments with human BMEC indicated that these cells constitutively secrete plasminogen activators, which might activate plasminogen on the surface of S. suis (Jobin et al., Reference Jobin, Fortin, Willson, Gottschalk and Grenier2005a).

Enolase

Similar to GAPDH, enolase is not only a cytosolic enzyme of the glycolysis pathway but also a surface-associated factor of various pathogenic streptococci involved in their interactions with host proteins (Pancholi and Fischetti, Reference Pancholi and Fischetti1998). One important function of streptococcal surface enolase (SEN) seems to be binding of plasmin(ogen). Activation of the fibrinolytic activity of host plasmin(ogen) on the bacterial surface is considered an important mechanism of tissue invasion. Esgleas et al. (Reference Esgleas, Li, Hancock, Harel, Dubreuil and Gottschalk2008) identified SEN of S. suis in search of a fibronectin-binding protein (Table 2). The authors confirmed that rSEN from S. suis has plasminogen- and fibronectin-binding activity with comparable high affinity. Noteworthy, SEN from S. suis is the only known SEN that binds to fibronectin. It is, however, unknown, whether S. suis fibronectin-binding properties depend on expression of SEN.

Enolase is an immunogenic protein as convalescent sera and sera from bacterin immunized piglets contain specific antibodies (Zhang and Lu, Reference Zhang and Lu2007). Immunization experiments of mice with recombinant enolase have elicited contradictory results. In BALB/c mice, significant protection against serotype 2 and 7 intra-peritoneal challenges was described using complete Freund's adjuvant (Zhang et al., Reference Zhang, Chen, Mu, Li, Zheng, Zhao, Chen and Jin2009). In contrast, no protection was observed in CD1 mice using QuilA as adjuvant (Esgleas et al. Reference Esgleas, Dominguez-Punaro, Li, Hancock, Harel, Dubreuil and Gottschalk2009, see also Table 4). As pathology in CD1, but not in BALB/c mice, includes meningitis, it remains questionable whether enolase immunization can protect against invasive S. suis infections.

Hemagglutinins

S. suis expresses a lectin-like adhesin that binds to the disaccharide Gal-(α1–4)-Gal of the glycolipid trihexosylceramide (GbO3) (Haataja et al., Reference Haataja, Tikkanen, Hytonen and Finne1996). This binding activity causes hemagglutination and is associated with an 18 kDa protein, which is classified into subtypes PN and PO (Tikkanen et al., Reference Tikkanen, Haataja, Francois-Gerard and Finne1995). N-acetylgalactosamine inhibits binding of PN only, whereas galactose inhibits binding of PN and PO. The Gal-(α1–4)-Gal binding adhesin is present in strains of various serotypes (Tikkanen et al., Reference Tikkanen, Haataja and Finne1996). Encapsulation is thought to interfere with the accessibility of this adhesin. However, preliminary immunization experiments in mice with the purified Gal-(α1–4)-Gal adhesin indicated induction of opsonizing antibodies (Tikkanen et al., Reference Tikkanen, Haataja and Finne1996).

A different hemagglutinin expressed by only a limited number of strains binds to a sialylated poly-N-acetyllactosamine-containing component on the surface of erythrocytes (Liukkonen et al., Reference Liukkonen, Haataja, Tikkanen, Kelm and Finne1992). To the best of our knowledge, the genes encoding these hemagglutinins have not been identified.

Lipoproteins

Prolipoproteins contain a conserved sequence element in the signal sequence called ‘lipobox’, which leads to a specific processing pathway. A prolipoprotein diacylglyceryl transferase (Lgt) transfers a diacylglyceryl moiety from a membrane lipid onto the conserved lipobox cysteine forming a thioether linkage. Subsequently, a lipoprotein signal peptidase (Lsp) cleaves the prolipoprotein in the ‘lipobox’, leaving the lipid-modified cysteine at the N-terminus (Hutchings et al., Reference Hutchings, Palmer, Harrington and Sutcliffe2009). A putative lgt gene has been annotated in the genomes of the Chinese S. suis STSS strains O5ZYH33 (SSUO5_1605) and 98HAH33 (SSU98_1615), but so far it has not been characterized in further detail (Chen et al., Reference Chen, Tang, Dong, Wang, Feng, Wang, Zheng, Pan, Liu, Li, Song, Zhu, Sun, Feng, Guo, Ju, Ge, Dong, Sun, Jiang, Wang, Yan, Yang, Wang, Gao, Yang, Wang and Yu2007). A highly homologous open reading frame (ORF) is also present in the genome of the European serotype 2 reference strain P1/7 (our unpublished results). An Lsp was identified by de Greeff et al. (Reference de Greeff, Hamilton, Sutcliffe, Buys, van Alphen and Smith2003). Sequence analysis of Lsp suggested four transmembrane spanning regions. An lsp knock out mutant of a virulent serotype 2 strain showed at least four band shifts of metabolically labeled lipoproteins indicating accumulation of some prolipoproteins in the lsp mutant. Accordingly, a band shift in this mutant in comparison to the wild-type strain was also observed in Western blot analysis with an antibody directed against the pneumococcal lipoprotein PsaA, a component of a Mn2+ transporter. In a competitive experimental infection experiment the lsp knock-out mutant was not attenuated in virulence as compared to the parental strain. These results are, however, difficult to interpret as some of the lipoproteins might be processed by an alternative, yet unidentified pathway as suggested by band shifts of the metabolically labeled lipoproteins in the respective mutant (de Greeff et al., Reference de Greeff, Hamilton, Sutcliffe, Buys, van Alphen and Smith2003).

In another recent study, three putative divalent-cation-binding lipoproteins of ABC transporters were identified and shown to be upregulated upon divalent-cation deprivation (Aranda et al., Reference Aranda, Garrido, Cortes, Llagostera and Barbe2008). Accordingly, the predicted regulator of Zn2+ and Mn2+ uptake AdcR was demonstrated to bind to two of the three promoters of the putative lipoprotein genes in vitro. Furthermore, in a mutant of a different zinc uptake regulator (Zur), putative Zn2+-binding lipoproteins were also found to be differentially regulated (Feng et al., Reference Feng, Li, Zhang, Zheng, Han, Wang, Yan, Tang and Gao2008). Interestingly, one of the three putative lipoproteins (SsuiDRAFT 0103) described by Aranda et al. (Reference Aranda, Garrido, Cortes, Llagostera and Barbe2008) induced significant protection in mice (Table 4). A second putative protective lipoprotein was identified in an immunoproteomic analysis of cell-wall associated proteins. The protein SSU98_1094 is predicted to be a lipoprotein of an uncharacterized ABC-type transport system (Geng et al., Reference Geng, Zhu, Yuan, Zhang, Li, Wang, Zheng, Wei, Cao, Wang and Jiang2008). Immunization of rats with rSSU98_1094 elicited high titers of opsonizing antibodies based on a whole human blood killing assay. Furthermore, convalescent sera from humans (meningitis or STSS patients) and piglets as well as from bacterin immunized piglets contain high serum antibody titers against SSU98_1094. Based on the results of this comprehensive immunoproteomic analysis of S. suis serotype 2, SSU98_1094 was suggested, together with two other surface-associated proteins (SSU98_0197 and SSU1664), as a vaccine candidate and diagnostic target (Geng et al., Reference Geng, Zhu, Yuan, Zhang, Li, Wang, Zheng, Wei, Cao, Wang and Jiang2008).

Table 4. Evaluation of protective efficacies of S. suis proteins

a Immunization experiments with three piglets suggested protection.

b CFA, complete Freund's adjuvant; IFA, incomplete Freund's adjuvant.

c Noteworthy, 50% mortality was observed in immunized piglets.

d Annotations in the genome of the North American reference strain 89/1591.

e The protective efficacies of eight other recombinant S. suis proteins were investigated in this study using the same protocol for immunization and challenge with the STSS strain 05ZYH33 (Liu et al., Reference Liu, Cheng, Wang, Pan, Cong, Pan, Wang, Zheng, Hu and Tang2009).

f Murein-associated protein.

Secreted factors

Secreted proteins may have various functions in bacterial pathogenesis. For instance, depending on the concentration and/or tissue, toxins may either damage host cells or interfere with activation pathways thereby modulating host immune responses. An obvious difference from surface-associated factors is that activity of a secreted factor does not require bacteria–host cell contact, but depends on diffusion in tissue in order to reach critical concentration. In S. suis, a number of secreted proteins have been identified, which most likely represent only a small part of the secretome of this pathogen (Table 3).

Suilysin

Suilysin is a pore-forming cholesterol-dependent cytotoxin (CDC) expressed by many but not all virulent S. suis strains. It shares 52% amino acid identity with pneumolysin, its closest known relative within the CDC protein family (Segers et al., Reference Segers, Kenter, de Haan and Jacobs1998). In contrast to pneumolysin it contains a signal sequence and is secreted. The mature protein has an estimated molecular weight of 54 kDa. The hemolytic activity of suilysin is lost upon oxidation and is inhibited by cholesterol (Jacobs et al., Reference Jacobs, Loeffen, vandenBerg and Storm1994). The susceptibility of erythrocytes to suilysin-mediated lysis shows some species specificity, with human group O erythrocytes being the most susceptible, followed by horse, sheep, cow and pig red blood cells (Gottschalk et al., Reference Gottschalk, Lacouture and Dubreuil1995).

Sequencing of S. suis genomes revealed additional genes encoding putative hemolysins (Chen et al., Reference Chen, Tang, Dong, Wang, Feng, Wang, Zheng, Pan, Liu, Li, Song, Zhu, Sun, Feng, Guo, Ju, Ge, Dong, Sun, Jiang, Wang, Yan, Yang, Wang, Gao, Yang, Wang and Yu2007). However, our Blast searches with the published S. suis genome sequences did not reveal a further putative CDC in S. suis (unpublished). In this respect, Table 1 of the publication by Chen et al. (Reference Chen, Tang, Dong, Wang, Feng, Wang, Zheng, Pan, Liu, Li, Song, Zhu, Sun, Feng, Guo, Ju, Ge, Dong, Sun, Jiang, Wang, Yan, Yang, Wang, Gao, Yang, Wang and Yu2007) listing ply and sly for S. suis is confusing. Apparently, both names refer to the suilysin gene (C. Chen, personal communication), and S. suis does not have a pneumolysin gene.

The sly gene displays very limited genetic diversity. Eighty percent of 208 investigated sly+S. suis isolates contained an identical sly allele as defined by restriction fragment length polymorphism (RFLP) analysis (King et al., Reference King, Heath, Luque, Tarradas, Dowson and Whatmore2001). Based on sequencing and Southern blot analysis it was suggested that the sly gene was acquired from a foreign source and laterally transferred from strain to strain by a mechanism including natural transformation and homologous recombination (Takamatsu et al., Reference Takamatsu, Osaki and Sekizaki2002).

In contrast to other virulence-associated genes such as mrp and fbps, expression of suilysin mRNA was found to be induced rather late during infection, i.e. at 48 h after intravenous application of the serotype 2 challenge strain (Tan et al., Reference Tan, Liu, Jin, Liu, Chen, Wu, Fu, Bei and Chen2008b). Noteworthy, manifestation of disease was observed at 20 h post infection. Depending on the tissue, a 2–4-fold induction of suilysin mRNA was described in comparison to in vitro expression. However, mRNA from in vitro cultures was collected at 3 h of cultivation. Therefore, it cannot be excluded that the postulated in vivo induction is simply due to the substantial upregulation of suilysin expression at the end of the exponential growth phase, as demonstrated by experiments measuring hemolytic activities (Gottschalk et al., Reference Gottschalk, Lacouture and Dubreuil1995) and sly promoter activity analysis (Lun and Willson, Reference Lun and Willson2005). Interestingly, transposon interruption of the gene manN endocing mannose permease IID of the mannose-specific phosphotransferase system resulted in a hyper-hemolytic phenotype due to increased suilysin expression. As this phenotype was, at least partially, reverted by complementation with manN, it was concluded that regulation of sly can be mediated by the mannose-specific phosphotransferase system (Lun and Willson, Reference Lun and Willson2005).

Suilysin has cytotoxic activity for various host cells, as shown for different epithelial cell lines (Norton et al., Reference Norton, Rolph, Ward, Bentley and Leigh1999; Lalonde et al., Reference Lalonde, Segura, Lacouture and Gottschalk2000), BMECs (Charland et al., Reference Charland, Nizet, Rubens, Kim, Lacouture and Gottschalk2000) and macrophages (Segura and Gottschalk, Reference Segura and Gottschalk2002). As determined by lactate dehydrogenase activity, more than 80% cytotoxicity was seen using 1–10 μg/ml suilysin (Charland et al., Reference Charland, Nizet, Rubens, Kim, Lacouture and Gottschalk2000; Lalonde et al., Reference Lalonde, Segura, Lacouture and Gottschalk2000; Segura and Gottschalk, Reference Segura and Gottschalk2002). However, suilysin also induces other cellular responses at sublytic concentrations (see below).

Invasion of epithelial cells by encapsulated serotype 2 strains is somewhat controversial, as already mentioned above. Norton et al. (Reference Norton, Rolph, Ward, Bentley and Leigh1999) described invasion of HEp-2 epithelial cells by encapsulated sly+ but not slyS. suis strains at a multiplicity of infection that was too low to cause suilysin-induced cell lysis. The authors suggested that suilysin mediates invasion of upper respiratory tract epithelial cells by virulent S. suis serotype 2 strains. Whether or not suilysin may be involved in invasion of (encapsulated and unencapsulated) S. suis in epithelial cells remains to be further elucidated.

Suilysin seems to contribute to the ability of virulent encapsulated serotype 2 strains to resist killing by porcine neutrophils in the presence of complete serum lacking specific IgG (Chabot-Roy et al., Reference Chabot-Roy, Willson, Segura, Lacouture and Gottschalk2006; Benga et al., Reference Benga, Fulde, Neis, Goethe and Valentin-Weigand2008). Addition of suilysin at sublytic concentration restored the phenotype of the isogenic sly mutant suggesting that some other mechanism in addition to cytotoxicity was involved (Chabot-Roy et al., Reference Chabot-Roy, Willson, Segura, Lacouture and Gottschalk2006). Our study indicated that expression of suilysin results in reduced internalization by porcine neutrophils but not reduced adherence to these cells (Benga et al., Reference Benga, Fulde, Neis, Goethe and Valentin-Weigand2008). No differences in the phenotype of the attenuated sly mutant were found between opsonizing and non-opsonizing conditions, in contrast to the work by Chabot-Roy et al. (Reference Chabot-Roy, Willson, Segura, Lacouture and Gottschalk2006). Only the latter is consistent with the speculation that suilysin leads to reduced complement deposition on the bacterial surface, as has been demonstrated for pneumolysin in the pathogenesis of pneumococci (Yuste et al., Reference Yuste, Botto, Paton, Holden and Brown2005). Alternatively, suilysin might actively interfere with the ability of neutrophils to kill S. suis.

Dominguez-Punaro et al. (Reference Dominguez-Punaro, Segura, Plante, Lacouture, Rivest and Gottschalk2007) investigated inflammatory reactions in the brain of CD1 mice after experimental infection with a suilysin producing serotype 2 strain. In agreement with a previous in vitro study (Graveline et al., Reference Graveline, Segura, Radzioch and Gottschalk2007), they detected upregulation of TLR 2, and to a lesser extent also TLR 3 but not TLR 4 mRNA. As discussed by the authors, this finding suggests a different mechanism of pathogenesis for suilysin in comparison to pneumolysin. Activation of TLR 4 by pneumolysin has been demonstrated to be crucial for a protective innate immune response against pneumococci (Malley et al., Reference Malley, Henneke, Morse, Cieslewicz, Lipsitch, Thompson, Kurt-Jones, Paton, Wessels and Golenbock2003).

Expression of cytokines (IL-1, IL-6 and TNF-α) and chemokines (IL-8 and MCP-1) in a whole-blood culture system did not show significant differences between the wild-type strain and a suilysin knock-out mutant (Segura et al., Reference Segura, Vanier, Al Numani, Lacouture, Olivier and Gottschalk2006). In earlier studies, this group had found that purified suilysin did not induce production of TNF-α and IL-6 by murine macrophages. In contrast, Lun et al. (Reference Lun, Perez-Casal, Connor and Willson2003) reported that suilysin triggered production of TNF-α in human monocytes and IL-6 production by pig pulmonary alveolar macrophages and monocytes. Furthermore, human endothelial cells secrete increased amounts of IL-6 and IL-8, but not MCP-1 after stimulation with purified suilysin at sublytic concentrations (Vadeboncoeur et al., Reference Vadeboncoeur, Segura, Al Numani, Vanier and Gottschalk2003). Sublytic concentrations of suilysin induced also transcription of the chemokine genes encoding IL-8 and MCP-1 in HEp-2 cells (our unpublished observations).

As multiple functions have been postulated for suilysin in interaction with host cells, severe attenuation of suilysin knock out mutants might be expected. However, attenuation in virulence of a suilysin knock-out mutant has only been demonstrated in mice (Allen et al., Reference Allen, Bolitho, Lindsay, Khan, Bryant, Norton, Ward, Leigh, Morgan, Riches, Eastty and Maskell2001). In contrast, in piglets different isogenic suilysin serotype 2 mutants were as virulent as the wild-type (Lun et al., Reference Lun, Perez-Casal, Connor and Willson2003), or were only slightly attenuated in virulence (Allen et al., Reference Allen, Bolitho, Lindsay, Khan, Bryant, Norton, Ward, Leigh, Morgan, Riches, Eastty and Maskell2001). On the other hand, the sly gene is more frequent among isolates from pigs with meningitis, septicemia and arthritis than in those from pigs with pneumonia (Staats et al., Reference Staats, Plattner, Stewart and Chengappa1999; King et al., Reference King, Heath, Luque, Tarradas, Dowson and Whatmore2001; Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006). Furthermore, geographical differences in prevalence of sly+ strains have been described. The most striking difference is the low prevalence of suilysin positive strains in North America in comparison to Europe and Asia (Gottschalk et al., Reference Gottschalk, Lebrun, Wisselink, Dubreuil, Smith and Vecht1998).

Immunization with purified suilysin completely protected BALB/c mice against challenge with a highly virulent serotype 2 strain (Jacobs et al., Reference Jacobs, Loeffen, vandenBerg and Storm1994). It is less clear whether suilysin is also a protective antigen in piglets. Challenge of three piglets immunized with purified suilysin suggested partial protection (Jacobs et al., Reference Jacobs, vandenBerg and Loeffen1996, see also Table 4). However, we observed no protection against challenge with virulent serotype 2 and 9 strains after intranasal immunization with a live vaccine, though seroconversion against suilysin and suilysin neutralizing antibodies were elicited (Kock et al., Reference Kock, Beineke, Seitz, Ganter, Waldmann, Valentin-Weigand and Baums2009).

In summary, suilysin is the only known secreted hemolysin of the CDC family in S. suis. Though suilysin is not essential for virulence of S. suis serotype 2 strains in pigs, in vitro experiments suggest that it may well have important functions in interactions with host cells.

Other hemolysins

Suppression subtractive hybridization analysis of the Chinese STSS strain HA9801 (used as tester) and the avirulent serotype 2 European strain T15 (driver) revealed, among other fragments, an ORF encoding a putative hemolysin type III. This DNA sequence was found in many virulent serotype 2 and 9 strains (Jiang et al., Reference Jiang, Fan and Lu2009). Further ORFs encoding putative hemolysins are annotated in the genomes of the sequenced S. suis serotype 2 strains (Chen et al., Reference Chen, Tang, Dong, Wang, Feng, Wang, Zheng, Pan, Liu, Li, Song, Zhu, Sun, Feng, Guo, Ju, Ge, Dong, Sun, Jiang, Wang, Yan, Yang, Wang, Gao, Yang, Wang and Yu2007, see also Table 3). However, at present there is no experimental evidence for expression of any other active hemolysin except suilysin.

Phospholipase C

Culture supernatants of S. suis serotype 2 strains induce degradation of phosphatidylcholine to diacylglycerol and choline phosphate (but not to phosphatidic acid), indicating that the tested strains secrete a phospholipase C (Jobin et al., Reference Jobin, Fortin, Willson, Gottschalk and Grenier2005a). Phospholipase C activity was identified in a search for potential factors in S. suis culture supernatants that are involved in the release of arachidonic acid from human BMECs observed in co-cultivation experiments with S. suis culture supernatants. Release of arachidonic acid was reduced in human BMECs treated with culture supernatants from a suilysin deficient mutant, but arachidonic acid was not released after treatment with suilysin. Based on these results the authors discussed a synergistic effect of suilysin and phospholipase C on the release of this important mediator by BMECs, which might play an important role in the pathogenesis of S. suis-associated meningitis.

EF

The 110-kDa EF encoded by the gene epf was identified as a protein associated with virulence in serotype 1 and 2 strains (Vecht et al., Reference Vecht, Wisselink, Jellema and Smith1991). The function of EF is still unknown. Isogenic epf mutants of serotypes 1 and 2 were as virulent as the wild-type in experimental infections indicating that EF is associated but not essential for virulence (Smith et al., Reference Smith, Vecht, Wisselink, StockhofeZurwieden, Biermann and Smits1996). So far, EF producing strains have been identified only in serotypes 1, 2, 1/2, 14 and 15 (Wisselink et al., Reference Wisselink, Smith, Stockhofe-Zurwieden, Peperkamp and Vecht2000).

Large variants (>110 kDa) of EF (EF*) are expressed by some serotype 2 strains. They are characterized by long C-terminal tandem repeats (each 76 amino acids long). These repetitive sequences are missing in the 110 kDa EF. In contrast, the N-terminus, namely the first 811 amino acids, of EF and EF* are nearly identical. Based on the repeats five different classes of EF* proteins have been differentiated (Smith et al., Reference Smith, Reek, Vecht, Gielkens and Smits1993). PCR assays are also available for differentiation of the different size variants of epf (Wisselink et al., Reference Wisselink, Joosten and Smith2002; Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006).

High mortality and morbidity was observed after experimental intranasal infection of newborn germfree piglets with MRP+ EF+ (referring to the 110 kDa protein) but not MRP+ EF* serotype 2 strains (Vecht et al., Reference Vecht, Wisselink, van Dijk and Smith1992). This finding is contradictory to the high prevalence of MRP+ EF* serotype 2 (or the respective genotype) strains among invasive isolates in various epidemiological studies (Martinez et al., Reference Martinez, de Castro, Pagnani, Nakazato, da Silveira and Gottschalk2003; Silva et al., Reference Silva, Baums, Rehm, Wisselink, Goethe and Valentin-Weigand2006). Furthermore, intravenous application of 108 CFU of an MRP+ EF* serotype 2 strain resulted in high mortality in piglets (our unpublished results).

Approximately 10% of the wild boars in Northwestern Germany carry mrp+ epf* cps2 strains on their tonsils, whereas mrp+ epf+ (encoding the 110 kDa protein) cps2 strains were undetectable among these animals, in contrast to control domesticated piglets from the same region (Baums et al., Reference Baums, Verkühlen, Rehm, Silva, Beyerbach, Pohlmeyer and Valentin-Weigand2007). Therefore, we speculated that factors associated with modern swine production have led to the selection of the highly virulent MRP+ EF+ (110 kDa protein) serotype 2 strains. The high virulence of these strains might, however, be specific for domestic pigs as S. suis serotype 2 isolates from humans in Europe frequently express the large EF* variants, but not the 110 kDa EF protein (Smith et al., Reference Smith, Reek, Vecht, Gielkens and Smits1993; Baums et al., Reference Baums, Verkühlen, Rehm, Silva, Beyerbach, Pohlmeyer and Valentin-Weigand2007).

Prevalences of various EF+ or EF* positive strains show substantial geographical variation. In contrast to Europe, MRP+ EF+ and MRP+ EF* serotype 2 strains have been detected only in single cases in North America (Gottschalk et al., Reference Gottschalk, Lebrun, Wisselink, Dubreuil, Smith and Vecht1998).

The 110-kDa EF and the high molecular variants of EF are immunogenic proteins. Convalescent phase sera from animals infected either with MRP+ EF+ or MRP+ EF* serotype 2 strains generally contain high antibody titers against EF (our unpublished results). Immunization with EF alone did not elicit protection against MRP+ EF+ serotype 2 challenges, but a vaccine containing purified MRP and EF together with a water-in-oil adjuvant was as protective as a bacterin (Wisselink et al., Reference Wisselink, Vecht, Stockhofe-Zurwieden and Smith2001). Nevertheless, a major problem of an EF-based vaccine is that many virulent S. suis strains, including all serotype 9 strains, do not express this factor.

Bacteriocin-like inhibitory substances (BLISs)

S. suis is not only an important invasive pathogen but also a successful colonizer of the upper respiratory, genital and alimentary tracts (Baele et al., Reference Baele, Chiers, Devriese, Smith, Wisselink, Vaneechoutte and Haesebrouck2001; Su et al., Reference Su, Yao, Perez-Gutierrez, Smidt and Zhu2008). As part of such microbial ecosystems S. suis interacts with numerous other bacteria including other S. suis strains. Melancon and Grenier (Reference Melancon and Grenier2003) demonstrated production of BLISs in 4 of 36 tested S. suis strains, which were active against other S. suis strains and other bacterial species associated with pigs. These BLISs were sensitive to proteinase K, pronase and elastase indicating that they are proteinaceous. BLISs are thought to be of advantage for the producing strain to compete in a microbial ecosystem, but this has not been reported for S. suis.

Immunoglobulin G-binding protein

S. suis strains of various serotypes express at least one IgG-binding protein (Serhir et al., Reference Serhir, Higgins, Foiry and Jacques1993). Serotype 2 strains secrete a 52-kDa IgG-binding protein that reacts with a large variety of mammalian IgG and IgA molecules (Serhir et al., Reference Serhir, Dubreuil, Higgins and Jacques1995). The binding of IgG does not depend on the glycosylation state of the immunoglobulin molecule. The S. suis protein exhibits lower IgG-binding affinities than protein A and protein G, especially with regard to human IgG. In contrast to protein A and protein G, the S. suis IgG-binding protein also targets chicken IgG.

Concluding remarks

The primary host of S. suis is the pig, but it may also cause very severe diseases in humans. The high diversity of this pathogen is reflected by presence of 33 serotypes and numerous genotypes, and the emergence of different pathotypes in Europe, North America and Asia. As in many other bacteria, both surface-associated and secreted factors contribute to virulence and pathogenesis. Recent progress in ‘omics’ research has generated a large amount of data on putative virulence-associated factors, and recent outbreaks of human infections in Asia have enormously fostered such analyses. On the other hand, experimental evidence for their possible function and biological role in infection is available for only a few of these factors. Understanding epidemiology and pathogenesis as well as improving control strategies, in particular vaccination, requires knowledge on bacterial factors that is more than speculation based on sequence data, for example. Therefore, this review provided an overview on currently available information about S. suis factors, mostly proteins, with respect to their features and function as well as their possible significance for epidemiological typing, pathogenesis and vaccination strategies. The article demonstrated the substantial progress in the field, but also reminds us of the many unsolved questions and future challenges.

Acknowledgements

Our studies are supported by the Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany (SFB587) and IDT Biologika GmbH Dessau-Tornau.

References

Aarestrup, FM, Jorsal, SE and Jensen, NE (1998). Serological characterization and antimicrobial susceptibility of Streptococcus suis isolates from diagnostic samples in Denmark during 1995 and 1996. Veterinary Microbiology 60: 5966.CrossRefGoogle ScholarPubMed
Allen, AG, Bolitho, S, Lindsay, H, Khan, S, Bryant, C, Norton, P, Ward, P, Leigh, J, Morgan, J, Riches, H, Eastty, S and Maskell, D (2001). Generation and characterization of a defined mutant of Streptococcus suis lacking suilysin. Infection and Immunity 69: 27322735.CrossRefGoogle ScholarPubMed
Allen, AG, Lindsay, H, Seilly, D, Bolitho, S, Peters, SE and Maskell, DJ (2004). Identification and characterisation of hyaluronate lyase from Streptococcus suis. Microbial Pathogenesis 36: 327335.CrossRefGoogle ScholarPubMed
Aranda, J, Garrido, ME, Cortes, P, Llagostera, M and Barbe, J (2008). Analysis of the protective capacity of three Streptococcus suis proteins induced under divalent-cation-limited conditions. Infection and Immunity 76: 15901598.CrossRefGoogle ScholarPubMed
Arends, JP and Zanen, HC (1988). Meningitis caused by Streptococcus suis in humans. Reviews of Infectious Diseases 10: 131137.CrossRefGoogle ScholarPubMed
Baele, M, Chiers, K, Devriese, LA, Smith, HE, Wisselink, HJ, Vaneechoutte, M and Haesebrouck, F (2001). The Gram-positive tonsillar and nasal flora of piglets before and after weaning. Journal of Applied Microbiology 91: 9971003.CrossRefGoogle ScholarPubMed
Barocchi, MA, Ries, J, Zogaj, X, Hemsley, C, Albiger, B, Kanth, A, Dahlberg, S, Fernebro, J, Moschioni, M, Masignani, V, Hultenby, K, Taddei, AR, Beiter, K, Wartha, F, von Euler, A, Covacci, A, Holden, DW, Normark, S, Rappuoli, R and Henriques-Normark, B (2006). A pneumococcal pilus influences virulence and host inflammatory responses. Proceedings of the National Academy of Sciences, USA 103: 28572862.CrossRefGoogle ScholarPubMed
Baums, CG, Kaim, U, Fulde, M, Ramachandran, G, Goethe, R and Valentin-Weigand, P (2006). Identification of a novel virulence determinant with serum opacification activity in Streptococcus suis. Infection and Immunity 74: 61546162.CrossRefGoogle ScholarPubMed
Baums, CG, Verkühlen, GJ, Rehm, T, Silva, LM, Beyerbach, M, Pohlmeyer, K and Valentin-Weigand, P (2007). Prevalence of Streptococcus suis genotypes in wild boars of Northwestern Germany. Applied and Environmental Microbiology 73: 711717.CrossRefGoogle ScholarPubMed
Baums, CG, Kock, C, Beineke, A, Bennecke, K, Goethe, R, Schroder, C, Waldmann, KH and Valentin-Weigand, P (2009). Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. Clinical and Vaccine Immunology 16: 200208.CrossRefGoogle Scholar
Beineke, A, Bennecke, K, Neis, C, Schröder, C, Waldmann, KH, Baumgartner, W, Valentin-Weigand, P and Baums, CG (2008). Comparative evaluation of virulence and pathology of Streptococcus suis serotypes 2 and 9 in experimentally infected growers. Veterinary Microbiology 128: 423430.CrossRefGoogle ScholarPubMed
Benga, L, Goethe, R, Rohde, M and Valentin-Weigand, P (2004). Non-encapsulated strains reveal novel insights in invasion and survival of Streptococcus suis in epithelial cells. Cellular Microbiology 6: 867881.CrossRefGoogle ScholarPubMed
Benga, L, Fulde, M, Neis, C, Goethe, R and Valentin-Weigand, P (2008). Polysaccharide capsule and suilysin contribute to extracellular survival of Streptococcus suis co-cultivated with primary porcine phagocytes. Veterinary Microbiology 132: 211219.CrossRefGoogle ScholarPubMed
Brassard, J, Gottschalk, M and Quessy, S (2001). Decrease of the adhesion of Streptococcus suis serotype 2 mutants to embryonic bovine tracheal cells and porcine tracheal rings. Canadian Journal of Veterinary Research 65: 156160.Google ScholarPubMed
Brassard, J, Gottschalk, M and Quessy, S (2004). Cloning and purification of the Streptococcus suis serotype 2 glyceraldehyde-3-phosphate dehydrogenase and its involvement as an adhesin. Veterinary Microbiology 102: 8794.CrossRefGoogle ScholarPubMed
Campo Sepulveda, EM, Altman, E, Kobisch, M, D'Allaire, S and Gottschalk, M (1996). Detection of antibodies against Streptococcus suis capsular type 2 using a purified capsular polysaccharide antigen-based indirect ELISA. Veterinary Microbiology 52: 113125.CrossRefGoogle ScholarPubMed
Chabot-Roy, G, Willson, P, Segura, M, Lacouture, S and Gottschalk, M (2006). Phagocytosis and killing of Streptococcus suis by porcine neutrophils. Microbial Pathogenesis 41: 2132.CrossRefGoogle ScholarPubMed
Charland, N, Kobisch, M, Martineau-Doize, B, Jacques, M and Gottschalk, M (1996). Role of capsular sialic acid in virulence and resistance to phagocytosis of Streptococcus suis capsular type 2. FEMS Immunology and Medical Microbiology 14: 195203.CrossRefGoogle ScholarPubMed
Charland, N, Harel, J, Kobisch, M, Lacasse, S and Gottschalk, M (1998). Streptococcus suis serotype 2 mutants deficient in capsular expression. Microbiology 144 (Pt 2): 325332.CrossRefGoogle ScholarPubMed
Charland, N, Nizet, V, Rubens, CE, Kim, KS, Lacouture, S and Gottschalk, M (2000). Streptococcus suis serotype 2 interactions with human brain microvascular endothelial cells. Infection and Immunity 68: 637643.CrossRefGoogle ScholarPubMed
Chen, C, Tang, J, Dong, W, Wang, C, Feng, Y, Wang, J, Zheng, F, Pan, X, Liu, D, Li, M, Song, Y, Zhu, X, Sun, H, Feng, T, Guo, Z, Ju, A, Ge, J, Dong, Y, Sun, W, Jiang, Y, Wang, J, Yan, J, Yang, H, Wang, X, Gao, GF, Yang, R, Wang, J and Yu, J (2007). A glimpse of streptococcal toxic shock syndrome from comparative genomics of Streptococcussuis 2 Chinese isolates. PLoS ONE 2: e315.CrossRefGoogle Scholar
Clifton-Hadley, FA and Alexander, TJ (1980). The carrier site and carrier rate of Streptococcus suis type II in pigs. Veterinary Record 107: 4041.CrossRefGoogle ScholarPubMed
Courtney, HS, Hasty, DL, Li, Y, Chiang, HC, Thacker, JL and Dale, JB (1999). Serum opacity factor is a major fibronectin-binding protein and a virulence determinant of M type 2 Streptococcus pyogenes. Molecular Microbiology 32: 8998.CrossRefGoogle Scholar
Cunin, R, Glansdorff, N, Pierard, A and Stalon, V (1986). Biosynthesis and metabolism of arginine in bacteria. Microbiological Reviews 50: 314352.CrossRefGoogle ScholarPubMed
de Greeff, A, Buys, H, Verhaar, R, Dijkstra, J, van Alphen, L and Smith, HE (2002). Contribution of fibronectin-binding protein to pathogenesis of Streptococcus suis serotype 2. Infection and Immunity 70: 13191325.CrossRefGoogle ScholarPubMed
de Greeff, A, Hamilton, A, Sutcliffe, IC, Buys, H, van Alphen, L and Smith, HE (2003). Lipoprotein signal peptidase of Streptococcus suis serotype 2. Microbiology 149: 13991407.CrossRefGoogle ScholarPubMed
Degnan, BA, Fontaine, MC, Doebereiner, AH, Lee, JJ, Mastroeni, P, Dougan, G, Goodacre, JA and Kehoe, MA (2000). Characterization of an isogenic mutant of Streptococcus pyogenes Manfredo lacking the ability to make streptococcal acid glycoprotein. Infection and Immunity 68: 24412448.CrossRefGoogle ScholarPubMed
Dominguez-Punaro, MC, Segura, M, Plante, MM, Lacouture, S, Rivest, S and Gottschalk, M (2007). Streptococcus suis serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection. Journal of Immunology 179: 18421854.CrossRefGoogle Scholar
Dramsi, S, Trieu-Cuot, P and Bierne, H (2005). Sorting sortases: a nomenclature proposal for the various sortases of Gram-positive bacteria. Research in Microbiology 156: 289297.CrossRefGoogle ScholarPubMed
Elliott, SD and Tai, JY (1978). The type-specific polysaccharides of Streptococcus suis. Journal of Experimental Medicine 148: 16991704.CrossRefGoogle ScholarPubMed
Elliott, SD, McCarty, M and Lancefield, RC (1977). Teichoic acids of group D streptococci with special reference to strains from pig meningitis (Streptococcus suis). Journal of Experimental Medicine 145: 490499.CrossRefGoogle Scholar
Elliott, SD, Clifton-Hadley, F and Tai, J (1980). Streptococcal infection in young pigs. V. An immunogenic polysaccharide from Streptococcus suis type 2 with particular reference to vaccination against streptococcal meningitis in pigs. Journal of Hygiene (London) 85: 275285.CrossRefGoogle Scholar
Esgleas, M, Lacouture, S and Gottschalk, M (2005). Streptococcus suis serotype 2 binding to extracellular matrix proteins. FEMS Microbiology Letters 244: 3340.CrossRefGoogle ScholarPubMed
Esgleas, M, Li, Y, Hancock, MA, Harel, J, Dubreuil, JD and Gottschalk, M (2008). Isolation and characterization of alpha-enolase, a novel fibronectin-binding protein from Streptococcus suis. Microbiology 154: 26682679.CrossRefGoogle ScholarPubMed
Esgleas, M, Dominguez-Punaro, MC, Li, Y, Hancock, MA, Harel, J, Dubreuil, JD and Gottschalk, M (2009). Immunization with SsEno fails to protect mice against challenge with Streptococcus suis serotype 2. FEMS Microbiology Letters 294: 8288.CrossRefGoogle ScholarPubMed
Feng, Y, Zheng, F, Pan, X, Sun, W, Wang, C, Dong, Y, Ju, AP, Ge, J, Liu, D, Liu, C, Yan, J, Tang, J and Gao, GF (2007). Existence and characterization of allelic variants of Sao, a newly identified surface protein from Streptococcus suis. FEMS Microbiology Letters 275: 8088.CrossRefGoogle Scholar
Feng, Y, Li, M, Zhang, H, Zheng, B, Han, H, Wang, C, Yan, J, Tang, J and Gao, GF (2008). Functional definition and global regulation of Zur, a zinc uptake regulator in a Streptococcus suis serotype 2 strain causing streptococcal toxic shock syndrome. Journal of Bacteriology 190: 75677578.CrossRefGoogle Scholar
Fittipaldi, N, Gottschalk, M, Vanier, G, Daigle, F and Harel, J (2007). Use of selective capture of transcribed sequences to identify genes preferentially expressed by Streptococcus suis upon interaction with porcine brain microvascular endothelial cells. Applied and Environmental Microbiology 73: 43594364.Google ScholarPubMed
Fittipaldi, N, Sekizaki, T, Takamatsu, D, Dominguez-Punaro, ML, Harel, J, Bui, NK, Vollmer, W and Gottschalk, M (2008a). Significant contribution of the pgdA gene to the virulence of Streptococcus suis. Molecular Microbiology 70: 11201135.CrossRefGoogle Scholar
Fittipaldi, N, Sekizaki, T, Takamatsu, D, Harel, J, Dominguez-Punaro, ML, Von Aulock, S, Draing, C, Marois, C, Kobisch, M and Gottschalk, M (2008b). D-alanylation of lipoteichoic acid contributes to the virulence of Streptococcus suis. Infection and Immunity 76: 35873594.Google Scholar
Fontaine, MC, Perez-Casal, J and Willson, PJ (2004). Investigation of a novel DNase of Streptococcus suis serotype 2. Infection and Immunity 72: 774781.CrossRefGoogle ScholarPubMed
Galina, L, Vecht, U, Wisselink, HJ and Pijoan, C (1996). Prevalence of various phenotypes of Streptococcus suis isolated from swine in the U.S.A. based on the presence of muraminidase-released protein and extracellular factor. Canadian Journal of Veterinary Research 60: 7274.Google ScholarPubMed
Geng, H, Zhu, L, Yuan, Y, Zhang, W, Li, W, Wang, J, Zheng, Y, Wei, K, Cao, W, Wang, H and Jiang, Y (2008). Identification and characterization of novel immunogenic proteins of Streptococcus suis serotype 2. Journal of Proteome Research 7: 41324142.CrossRefGoogle ScholarPubMed
Gottschalk, M and Segura, M (2000). The pathogenesis of the meningitis caused by Streptococcus suis: the unresolved questions. Veterinary Microbiology 76: 259272.CrossRefGoogle ScholarPubMed
Gottschalk, MG, Lacouture, S and Dubreuil, JD (1995). Characterization of Streptococcus suis capsular type 2 haemolysin. Microbiology 141: 189195.CrossRefGoogle ScholarPubMed
Gottschalk, M, Lebrun, A, Wisselink, H, Dubreuil, JD, Smith, H and Vecht, U (1998). Production of virulence-related proteins by Canadian strains of Streptococcus suis capsular type 2. Canadian Journal of Veterinary Research–Revue Canadienne de Recherche Veterinaire 62: 7579.Google ScholarPubMed
Gottschalk, M, Higgins, R and Quessy, S (1999). Dilemma of the virulence of Streptococcus suis strains. Journal of Clinical Microbiology 37: 42024203.CrossRefGoogle Scholar
Gottschalk, M, Segura, M and Xu, J (2007). Streptococcus suis infections in humans: the Chinese experience and the situation in North America. Animal Health Research Reviews 8: 2945.CrossRefGoogle ScholarPubMed
Graveline, R, Segura, M, Radzioch, D and Gottschalk, M (2007). TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. International Immunology 19: 375389.CrossRefGoogle ScholarPubMed
Gruening, P, Fulde, M, Valentin-Weigand, P and Goethe, R (2006). Structure, regulation, and putative function of the arginine deiminase system of Streptococcus suis. Journal of Bacteriology 188: 361369.CrossRefGoogle ScholarPubMed
Haataja, S, Tikkanen, K, Hytonen, J and Finne, J (1996). The Gal alpha 1–4 Gal-binding adhesin of Streptococcus suis, a gram-positive meningitis-associated bacterium. Advances in Experimental Medicine and Biology 408: 2534.CrossRefGoogle ScholarPubMed
Higgins, R and Gottschalk, M (2005). Streptococcal diseases. In: Straw, B, Allaire, SD, Mengeling, W and Taylor, D (eds) Diseases of Swine. Ames, IA: Iowa State University Press, pp. 769783.Google Scholar
Hutchings, MI, Palmer, T, Harrington, DJ and Sutcliffe, IC (2009). Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold 'em, knowing when to fold 'em. Trends in Microbiology 17: 1321.CrossRefGoogle ScholarPubMed
Jacobs, AAC, Loeffen, PLW, vandenBerg, AJG and Storm, PK (1994). Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infection and Immunity 62: 17421748.CrossRefGoogle ScholarPubMed
Jacobs, AAC, vandenBerg, AJG and Loeffen, PLW (1996). Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. Veterinary Record 139: 225228.CrossRefGoogle ScholarPubMed
Jacques, M, Gottschalk, M, Foiry, B and Higgins, R (1990). Ultrastructural study of surface components of Streptococcus suis. Journal of Bacteriology 172: 28332838.CrossRefGoogle ScholarPubMed
Jiang, H, Fan, HJ and Lu, CP (2009). Identification and distribution of putative virulent genes in strains of Streptococcus suis serotype 2. Veterinary Microbiology 133: 309316.CrossRefGoogle ScholarPubMed
Jobin, MC and Grenier, D (2003). Identification and characterization of four proteases produced by Streptococcus suis. FEMS Microbiology Letters 220: 113119.CrossRefGoogle ScholarPubMed
Jobin, MC, Brassard, J, Quessy, S, Gottschalk, M and Grenier, D (2004). Acquisition of host plasmin activity by the swine pathogen Streptococcus suis serotype 2. Infection and Immunity 72: 606610.CrossRefGoogle ScholarPubMed
Jobin, MC, Fortin, J, Willson, PJ, Gottschalk, M and Grenier, D (2005a). Acquisition of plasmin activity and induction of arachidonic acid release by Streptococcus suis in contact with human brain microvascular endothelial cells. FEMS Microbiology Letters 252: 105111.CrossRefGoogle ScholarPubMed
Jobin, MC, Martinez, G, Motard, J, Gottschalk, M and Grenier, D (2005b). Cloning, purification, and enzymatic properties of dipeptidyl peptidase IV from the swine pathogen Streptococcus suis. Journal of Bacteriology 187: 795799.CrossRefGoogle ScholarPubMed
King, SJ, Heath, PJ, Luque, I, Tarradas, C, Dowson, CG and Whatmore, AM (2001). Distribution and genetic diversity of suilysin in Streptococcus suis isolated from different diseases of pigs and characterization of the genetic basis of suilysin absence. Infection and Immunity 69: 75727582.CrossRefGoogle ScholarPubMed
King, SJ, Allen, AG, Maskell, DJ, Dowson, CG and Whatmore, AM (2004). Distribution, genetic diversity, and variable expression of the gene encoding hyaluronate lyase within the Streptococcus suis population. Journal of Bacteriology 186: 47404747.CrossRefGoogle ScholarPubMed
Kock, C, Beineke, A, Seitz, M, Ganter, M, Waldmann, K, Valentin-Weigand, P and Baums, CG (2009). Intranasal immunization with a live Streptococcus suis isogenic ofs mutant elicited suilysin-neutralization titers but failed to induce opsonizing antibodies and protection. Veterinary Immunology and Immunopathology in press.CrossRefGoogle ScholarPubMed
Lalonde, M, Segura, M, Lacouture, S and Gottschalk, M (2000). Interactions between Streptococcus suis serotype 2 and different epithelial cell lines. Microbiology 146: 19131921.CrossRefGoogle ScholarPubMed
Li, M, Wang, C, Feng, Y, Pan, X, Cheng, G, Wang, J, Ge, J, Zheng, F, Cao, M, Dong, Y, Liu, D, Wang, J, Lin, Y, Du, H, Gao, GF, Wang, X, Hu, F and Tang, J (2008). SalK/SalR, a two-component signal transduction system, is essential for full virulence of highly invasive Streptococcus suis serotype 2. PLoS ONE 3: e2080.CrossRefGoogle ScholarPubMed
Li, W, Liu, L, Chen, H and Zhou, R (2009). Identification of Streptococcus suis genes preferentially expressed under iron starvation by selective capture of transcribed sequences. FEMS Microbiology Letters 292: 123133.CrossRefGoogle ScholarPubMed
Li, Y, Martinez, G, Gottschalk, M, Lacouture, S, Willson, P, Dubreuil, JD, Jacques, M and Harel, J (2006). Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs. Infection and Immunity 74: 305312.CrossRefGoogle ScholarPubMed
Li, Y, Gottschalk, M, Esgleas, M, Lacouture, S, Dubreuil, JD, Willson, P and Harel, J (2007). Immunization with recombinant Sao protein confers protection against Streptococcus suis infection. Clinical and Vaccine Immunology 14: 937943.CrossRefGoogle ScholarPubMed
Liu, L, Cheng, G, Wang, C, Pan, X, Cong, Y, Pan, Q, Wang, J, Zheng, F, Hu, F and Tang, J (2009). Identification and experimental verification of protective antigens against Streptococcus suis serotype 2 based on genome sequence analysis. Current Microbiology 58: 1117.CrossRefGoogle ScholarPubMed
Liukkonen, J, Haataja, S, Tikkanen, K, Kelm, S and Finne, J (1992). Identification of N-acetylneuraminyl alpha 2–>3 poly-N-acetyllactosamine glycans as the receptors of sialic acid-binding Streptococcus suis strains. Journal of Biological Chemistry 267: 2110521111.CrossRefGoogle Scholar
Lun, S and Willson, PJ (2005). Putative mannose-specific phosphotransferase system component IID represses expression of suilysin in serotype 2 Streptococcus suis. Veterinary Microbiology 105: 169180.CrossRefGoogle ScholarPubMed
Lun, SC, Perez-Casal, J, Connor, W and Willson, PJ (2003). Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2. Microbial Pathogenesis 34: 2737.CrossRefGoogle ScholarPubMed
Lun, ZR, Wang, QP, Chen, XG, Li, AX and Zhu, XQ (2007). Streptococcus suis: an emerging zoonotic pathogen. Lancet Infectious Diseases 7: 201209.CrossRefGoogle ScholarPubMed
Madsen, LW, Svensmark, B, Elvestad, K, Aalbaek, B and Jensen, HE (2002). Streptococcus suis serotype 2 infection in pigs: new diagnostic and pathogenetic aspects. Journal of Comparative Pathology 126: 5765.CrossRefGoogle ScholarPubMed
Mai, NT, Hoa, NT, Nga, TV, Linh, LD, Chau, TT, Sinh, DX, Phu, NH, Chuong, LV, Diep, TS, Campbell, J, Nghia, HD, Minh, TN, Chau, NV, de Jong, MD, Chinh, NT, Hien, TT, Farrar, J and Schultsz, C (2008). Streptococcus suis meningitis in adults in Vietnam. Clinical Infectious Diseases 46: 659667.Google ScholarPubMed
Malley, R, Henneke, P, Morse, SC, Cieslewicz, MJ, Lipsitch, M, Thompson, CM, Kurt-Jones, E, Paton, JC, Wessels, MR and Golenbock, DT (2003). Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proceedings of the National Academy of Sciences, USA 100: 19661971.CrossRefGoogle ScholarPubMed
Marques, MB, Kasper, DL, Pangburn, MK and Wessels, MR (1992). Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infection and Immunity 60: 39863993.CrossRefGoogle ScholarPubMed
Martinez, G, de Castro, AFP, Pagnani, KJR, Nakazato, G, da Silveira, WD and Gottschalk, M (2003). Clonal distribution of an atypical MRP+, EF*, and suilysin(+) phenotype of virulent Streptococcus suis serotype 2 strains in Brazil. Canadian Journal of Veterinary Research–Revue Canadienne de Recherche Veterinaire 67: 5255.Google ScholarPubMed
Mazmanian, SK, Liu, G, Ton-That, H and Schneewind, O (1999). Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 285: 760763.CrossRefGoogle ScholarPubMed
Melancon, D and Grenier, D (2003). Production and properties of bacteriocin-like inhibitory substances from the swine pathogen Streptococcus suis serotype 2. Applied and Environmental Microbiology 69: 44824488.CrossRefGoogle ScholarPubMed
Messier, S, Lacouture, S and Gottschalk, M (2008). Distribution of Streptococcus suis capsular types from 2001 to 2007. Canadian Veterinary Journal 49: 461462.Google ScholarPubMed
Norton, PM, Rolph, C, Ward, PN, Bentley, RW and Leigh, JA (1999). Epithelial invasion and cell lysis by virulent strains of Streptococcus suis is enhanced by the presence of suilysin. FEMS Immunology and Medical Microbiology 26: 2535.CrossRefGoogle ScholarPubMed
Okwumabua, O and Chinnapapakkagari, S (2005). Identification of the gene encoding a 38-kilodalton immunogenic and protective antigen of Streptococcus suis. Clinical and Diagnostic Laboratory Immunology 12: 484490.Google ScholarPubMed
Osaki, M, Takamatsu, D, Shimoji, Y and Sekizaki, T (2002). Characterization of Streptococcus suis genes encoding proteins homologous to sortase of Gram-positive bacteria. Journal of Bacteriology 184: 971982.CrossRefGoogle ScholarPubMed
Osaki, M, Takamatsu, D, Shimoji, Y and Sekizaki, T (2003). Allelic variation in srtAs of Streptococcus suis strains. FEMS Microbiology Letters 219: 195201.CrossRefGoogle ScholarPubMed
Pan, X, Ge, J, Li, M, Wu, B, Wang, C, Wang, J, Feng, Y, Yin, Z, Zheng, F, Cheng, G, Sun, W, Ji, H, Hu, D, Shi, P, Feng, X, Hao, X, Dong, R, Hu, F and Tang, J (2009). The orphan response regulator CovR: a globally negative modulator of virulence in Streptococcus suis serotype 2. Journal of Bacteriology 191: 26012612.CrossRefGoogle ScholarPubMed
Pancholi, V and Fischetti, VA (1992). A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity. Journal of Experimental Medicine 176: 415426.CrossRefGoogle Scholar
Pancholi, V and Fischetti, VA (1998). alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. Journal of Biological Chemistry 273: 1450314515.CrossRefGoogle ScholarPubMed
Perch, B, Pedersen, KB and Henrichsen, J (1983). Serology of capsulated streptococci pathogenic for pigs: six new serotypes of Streptococcus suis. Journal of Clinical Microbiology 17: 993996.CrossRefGoogle ScholarPubMed
Quessy, S, Dubreuil, JD, Jacques, M, Malouin, F and Higgins, R (1994). Increase of capsular material thickness following in vivo growth of virulent Streptococcus suis serotype 2 strains. FEMS Microbiology Letters 115: 1926.CrossRefGoogle ScholarPubMed
Quessy, S, Busque, P, Higgins, R, Jacques, M and Dubreuil, JD (1997). Description of an albumin binding activity for Streptococcus suis serotype 2. FEMS Microbiology Letters 147: 245250.CrossRefGoogle ScholarPubMed
Segers, RPAM, Kenter, T, de Haan, LAM and Jacobs, AAC (1998). Characterisation of the gene encoding suilysin from Streptococcus suis and expression in field strains. FEMS Microbiology Letters 167: 255261.CrossRefGoogle ScholarPubMed
Segura, M and Gottschalk, M (2002). Streptococcus suis interactions with the murine macrophage cell line J774: adhesion and cytotoxicity. Infection and Immunity 70: 43124322.CrossRefGoogle ScholarPubMed
Segura, MA, Cleroux, P and Gottschalk, M (1998). Streptococcus suis and group B Streptococcus differ in their interactions with murine macrophages. FEMS Immunology and Medical Microbiology 21: 189195.CrossRefGoogle ScholarPubMed
Segura, M, Gottschalk, M and Olivier, M (2004). Encapsulated Streptococcus suis inhibits activation of signaling pathways involved in phagocytosis. Infection and Immunity 72: 53225330.CrossRefGoogle ScholarPubMed
Segura, M, Vanier, G, Al Numani, D, Lacouture, S, Olivier, M and Gottschalk, M (2006). Proinflammatory cytokine and chemokine modulation by Streptococcus suis in a whole-blood culture system. FEMS Immunology and Medical Microbiology 47: 92106.CrossRefGoogle Scholar
Serhir, B, Higgins, R, Foiry, B and Jacques, M (1993). Detection of immunoglobulin-G-binding proteins in Streptococcus suis. Journal of General Microbiology 139: 29532958.CrossRefGoogle ScholarPubMed
Serhir, B, Dubreuil, D, Higgins, R and Jacques, M (1995). Purification and characterization of a 52-kilodalton immunoglobulin G-binding protein from Streptococcus suis capsular type 2. Journal of Bacteriology 177: 38303836.CrossRefGoogle ScholarPubMed
Silva, LM, Baums, CG, Rehm, T, Wisselink, HJ, Goethe, R and Valentin-Weigand, P (2006). Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Veterinary Microbiology 115: 117127.CrossRefGoogle ScholarPubMed
Smith, HE, Vecht, U, Gielkens, ALJ and Smits, MA (1992). Cloning and nucleotide-sequence of the gene encoding the 136-kilodalton surface protein (muramidase-released protein) of Streptococcus suis type-2. Infection and Immunity 60: 23612367.CrossRefGoogle ScholarPubMed
Smith, HE, Reek, FH, Vecht, U, Gielkens, ALJ and Smits, MA (1993). Repeats in an extracellular protein of weakly pathogenic strains of Streptococcus suis type-2 are absent in pathogenic strains. Infection and Immunity 61: 33183326.CrossRefGoogle Scholar
Smith, HE, Vecht, U, Wisselink, HJ, StockhofeZurwieden, N, Biermann, Y and Smits, MA (1996). Mutants of Streptococcus suis types 1 and 2 impaired in expression of muramidase-released protein and extracellular protein induce disease in newborn germfree pigs. Infection and Immunity 64: 44094412.CrossRefGoogle ScholarPubMed
Smith, HE, Damman, M, van der Velde, J, Wagenaar, F, Wisselink, HJ, Stockhofe-Zurwieden, N and Smits, MA (1999). Identification and characterization of the cps locus of Streptococcus suis serotype 2: the capsule protects against phagocytosis and is an important virulence factor. Infection and Immunity 67: 17501756.CrossRefGoogle ScholarPubMed
Smith, HE, de Vries, R, van't Slot, R and Smits, MA (2000). The cps locus of Streptococcus suis serotype 2: genetic determinant for the synthesis of sialic acid. Microbial Pathogenesis 29: 127134.CrossRefGoogle ScholarPubMed
Smith, HE, Buijs, H, de Vries, RR, Wisselink, HJ, Stockhofe-Zurwieden, N and Smits, MA (2001). Environmentally regulated genes of Streptococcus suis: identification by the use of iron-restricted conditions in vitro and by experimental infection of piglets. Microbiology 147: 271280.CrossRefGoogle ScholarPubMed
Song, L and Pachter, JS (2004). Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvascular Research 67: 7889.CrossRefGoogle ScholarPubMed
Staats, JJ, Plattner, BL, Stewart, GC and Chengappa, MM (1999). Presence of the Streptococcus suis suilysin gene and expression of MRP and EF correlates with high virulence in Streptococcus suis type 2 isolates. Veterinary Microbiology 70: 201211.CrossRefGoogle ScholarPubMed
Su, Y, Yao, W, Perez-Gutierrez, ON, Smidt, H and Zhu, WY (2008). Changes in abundance of Lactobacillus spp. and Streptococcus suis in the stomach, jejunum and ileum of piglets after weaning. FEMS Microbiology Ecology 66: 546555.CrossRefGoogle ScholarPubMed
Takamatsu, D, Osaki, M and Sekizaki, T (2002). Evidence for lateral transfer of the suilysin gene region of Streptococcus suis. Journal of Bacteriology 184: 20502057.CrossRefGoogle ScholarPubMed
Takamatsu, D, Osaki, M, Tharavichitkul, P, Takai, S and Sekizaki, T (2008). Allelic variation and prevalence of serum opacity factor among the Streptococcus suis population. Journal of Medical Microbiology 57: 488494.Google ScholarPubMed
Takamatsu, D, Nishino, H, Ishiji, T, Ishii, J, Osaki, M, Fittipaldi, N, Gottschalk, M, Tharavichitkul, P, Takai, S and Sekizaki, T (2009). Genetic organization and preferential distribution of putative pilus gene clusters in Streptococcus suis. Veterinary Microbiology 138: 132139.CrossRefGoogle ScholarPubMed
Tan, C, Fu, S, Liu, M, Jin, M, Liu, J, Bei, W and Chen, H (2008a). Cloning, expression and characterization of a cell wall surface protein, 6-phosphogluconate-dehydrogenase, of Streptococcus suis serotype 2. Veterinary Microbiology 130: 363370.CrossRefGoogle ScholarPubMed
Tan, C, Liu, M, Jin, M, Liu, J, Chen, Y, Wu, T, Fu, T, Bei, W and Chen, H (2008b). The key virulence-associated genes of Streptococcus suis type 2 are upregulated and differentially expressed in vivo. FEMS Microbiology Letters 278: 108114.CrossRefGoogle ScholarPubMed
Tan, C, Liu, M, Liu, J, Yuan, F, Fu, S, Liu, Y, Jin, M, Bei, W and Chen, H (2009). Vaccination with Streptococcus suis serotype 2 recombinant 6PGD protein provides protection against S. suis infection in swine. FEMS Microbiology Letters 296: 7883.CrossRefGoogle ScholarPubMed
Tang, J, Wang, C, Feng, Y, Yang, W, Song, H, Chen, Z, Yu, H, Pan, X, Zhou, X, Wang, H, Wu, B, Wang, H, Zhao, H, Lin, Y, Yue, J, Wu, Z, He, X, Gao, F, Khan, AH, Wang, J, Zhao, GP, Wang, Y, Wang, X, Chen, Z and Gao, GF (2006). Streptococcal toxic shock syndrome caused by Streptococcus suis serotype 2. PLoS Medicine 3: e151.CrossRefGoogle ScholarPubMed
Telford, JL, Barocchi, MA, Margarit, I, Rappuoli, R and Grandi, G (2006). Pili in gram-positive pathogens. Nature Reviews Microbiology 4: 509519.CrossRefGoogle ScholarPubMed
Tenenbaum, T, Papandreou, T, Gellrich, D, Friedrichs, U, Seibt, A, Adam, R, Wewer, C, Galla, HJ, Schwerk, C and Schroten, H (2009). Polar bacterial invasion and translocation of Streptococcus suis across the blood-cerebrospinal fluid barrier in vitro. Cellular Microbiology 11: 323336.CrossRefGoogle ScholarPubMed
Tian, Y, Aarestrup, FM and Lu, CP (2004). Characterization of Streptococcus suis serotype 7 isolates from diseased pigs in Denmark. Veterinary Microbiology 103: 5562.CrossRefGoogle ScholarPubMed
Tikkanen, K, Haataja, S, Francois-Gerard, C and Finne, J (1995). Purification of a galactosyl-alpha 1–4-galactose-binding adhesin from the Gram-positive meningitis-associated bacterium Streptococcus suis. Journal of Biological Chemistry 270: 2887428878.Google ScholarPubMed
Tikkanen, K, Haataja, S and Finne, J (1996). The galactosyl-(alpha 1–4-galactose-binding adhesin of Streptococcus suis: occurrence in strains of different hemagglutination activities and induction of opsonic antibodies. Infection and Immunity 64: 36593665.CrossRefGoogle ScholarPubMed
Ton-That, H, Liu, G, Mazmanian, SK, Faull, KF and Schneewind, O (1999). Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. Proceedings of the National Academy of Sciences, USA 96: 1242412429.CrossRefGoogle ScholarPubMed
Ton-That, H, Marraffini, LA and Schneewind, O (2004). Sortases and pilin elements involved in pilus assembly of Corynebacterium diphtheriae. Molecular Microbiology 53: 251261.CrossRefGoogle ScholarPubMed
Vadeboncoeur, N, Segura, M, Al Numani, D, Vanier, G and Gottschalk, M (2003). Pro-inflammatory cytokine and chemokine release by human brain microvascular endothelial cells stimulated by Streptococcus suis serotype 2. FEMS Immunology and Medical Microbiology 35: 4958.CrossRefGoogle ScholarPubMed
Vanier, G, Segura, M, Friedl, P, Lacouture, S and Gottschalk, M (2004). Invasion of porcine brain microvascular endothelial cells by Streptococcus suis serotype 2. Infection and Immunity 72: 14411449.CrossRefGoogle ScholarPubMed
Vanier, G, Segura, M and Gottschalk, M (2007). Characterization of the invasion of porcine endothelial cells by Streptococcus suis serotype 2. Canadian Journal of Veterinary Research 71: 8189.Google ScholarPubMed
Vanier, G, Sekizaki, T, Dominguez-Punaro, MC, Esgleas, M, Osaki, M, Takamatsu, D, Segura, M and Gottschalk, M (2008). Disruption of srtA gene in Streptococcus suis results in decreased interactions with endothelial cells and extracellular matrix proteins. Veterinary Microbiology 127: 417424.CrossRefGoogle ScholarPubMed
Vanier, G, Fittipaldi, N, Slater, JD, Dominguez-Punaro, ML, Rycroft, AN, Segura, M, Maskell, DJ and Gottschalk, M (2009). New putative virulence factors of Streptococcus suis involved in invasion of porcine brain microvascular endothelial cells. Microbial Pathogenesis 46: 1320.CrossRefGoogle ScholarPubMed
Vecht, U, Wisselink, HJ, Jellema, ML and Smith, HE (1991). Identification of 2 proteins associated with virulence of Streptococcus suis type-2. Infection and Immunity 59: 31563162.CrossRefGoogle ScholarPubMed
Vecht, U, Wisselink, HJ, van Dijk, JE and Smith, HE (1992). Virulence of Streptococcus suis type 2 strains in newborn germfree pigs depends on phenotype. Infection and Immunity 60: 550556.CrossRefGoogle ScholarPubMed
Vecht, U, Stockhofe-Zurwieden, N, Tetenburg, BJ, Wisselink, HJ and Smith, HE (1997). Murine and pig models of Streptococcus suis type 2 infections are incompatible. Streptococci and the Host 418: 827829.CrossRefGoogle ScholarPubMed
Vollmer, W (2008). Structural variation in the glycan strands of bacterial peptidoglycan. FEMS Microbiology Reviews 32: 287306.CrossRefGoogle ScholarPubMed
Vollmer, W, Blanot, D and de Pedro, MA (2008). Peptidoglycan structure and architecture. FEMS Microbiology Reviews 32: 149167.CrossRefGoogle ScholarPubMed
Wang, C, Li, M, Feng, Y, Zheng, F, Dong, Y, Pan, X, Cheng, G, Dong, R, Hu, D, Feng, X, Ge, J, Liu, D, Wang, J, Cao, M, Hu, F and Tang, J (2009). The involvement of sortase A in high virulence of STSS-causing Streptococcus suis serotype 2. Archives of Microbiology 191: 2333.CrossRefGoogle ScholarPubMed
Wei, Z, Li, R, Zhang, A, He, H, Hua, Y, Xia, J, Cai, X, Chen, H and Jin, M (2009). Characterization of Streptococcus suis isolates from the diseased pigs in China between 2003 and 2007. Veterinary Microbiology 137: 196201.CrossRefGoogle Scholar
Wertheim, HF, Nghia, HD, Taylor, W and Schultsz, C (2009). Streptococcus suis: an emerging human pathogen. Clinical Infectious Diseases 48: 617625.CrossRefGoogle ScholarPubMed
Wibawan, IW and Lammler, C (1994). Relation between encapsulation and various properties of Streptococcus suis. Zentralblatt Veterinarmedizin RheineB 41: 453459.Google ScholarPubMed
Williams, AE and Blakemore, WF (1990). Pathology of Streptococcal meningitis following intravenous intracisternal and natural routes of infection. Neuropathology and Applied Neurobiology 16: 345356.CrossRefGoogle ScholarPubMed
Winterhoff, N, Goethe, R, Gruening, P, Rohde, M, Kalisz, H, Smith, HE and Valentin-Weigand, P (2002). Identification and characterization of two temperature-induced surface-associated proteins of Streptococcus suis with high homologies to members of the arginine deiminase system of Streptococcus pyogenes. Journal of Bacteriology 184: 67686776.CrossRefGoogle ScholarPubMed
Wisselink, HJ, Smith, HE, Stockhofe-Zurwieden, N, Peperkamp, K and Vecht, U (2000). Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European countries. Veterinary Microbiology 74: 237248.CrossRefGoogle ScholarPubMed
Wisselink, HJ, Vecht, U, Stockhofe-Zurwieden, N and Smith, HE (2001). Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine. The Veterinary Record 148: 473477.CrossRefGoogle ScholarPubMed
Wisselink, HJ, Joosten, JJ and Smith, HE (2002). Multiplex PCR assays for simultaneous detection of six major serotypes and two virulence-associated phenotypes of Streptococcus suis in tonsillar specimens from pigs. Journal of Clinical Microbiology 40: 29222929.CrossRefGoogle ScholarPubMed
Wu, Z, Zhang, W and Lu, C (2008a). Comparative proteome analysis of secreted proteins of Streptococcus suis serotype 9 isolates from diseased and healthy pigs. Microbial Pathogenesis 45: 159166.CrossRefGoogle ScholarPubMed
Wu, Z, Zhang, W and Lu, C (2008b). Immunoproteomic assay of surface proteins of Streptococcus suis serotype 9. FEMS Immunology and Medical Microbiology 53: 5259.CrossRefGoogle ScholarPubMed
Ye, C, Zhu, X, Jing, H, Du, H, Segura, M, Zheng, H, Kan, B, Wang, L, Bai, X, Zhou, Y, Cui, Z, Zhang, S, Jin, D, Sun, N, Luo, X, Zhang, J, Gong, Z, Wang, X, Wang, L, Sun, H, Li, Z, Sun, Q, Liu, H, Dong, B, Ke, C, Yuan, H, Wang, H, Tian, K, Wang, Y, Gottschalk, M and Xu, J (2006). Streptococcus suis sequence type 7 outbreak, Sichuan, China. Emerging Infectious Disease 12: 12031208.CrossRefGoogle ScholarPubMed
Yuste, J, Botto, M, Paton, JC, Holden, DW and Brown, JS (2005). Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae septicemia. Journal of Immunology 175: 18131819.CrossRefGoogle ScholarPubMed
Zhang, A, Chen, B, Mu, X, Li, R, Zheng, P, Zhao, Y, Chen, H and Jin, M (2009). Identification and characterization of a novel protective antigen, enolase of Streptococcus suis serotype 2. Vaccine 27: 13481353.CrossRefGoogle ScholarPubMed
Zhang, W and Lu, CP (2007). Immunoproteomics of extracellular proteins of Chinese virulent strains of Streptococcus suis type 2. Proteomics 7: 44684476.CrossRefGoogle ScholarPubMed
Zuniga, M, Perez, G and Gonzalez-Candelas, F (2002). Evolution of arginine deiminase (ADI) pathway genes. Molecular and Phylogenetic Evolution 25: 429444.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Confirmed (c) and proposed (p) S. suis proteins with a CWS

Figure 1

Table 2. Confirmed (c) and proposed (p) surface-associated proteins of S. suis without a CWSa

Figure 2

Table 3. Proposed (p) and confirmed (c) secreted factors of S. suis (selection)

Figure 3

Table 4. Evaluation of protective efficacies of S. suis proteins